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In addition to the well-characterized genomic mechanism of steroid action that uses
intracellular receptors, steroid hormones also signal through nongenomic processes
that use membrane receptors. A membrane receptor for corticosterone (CORT) has
been described in brains of the roughskin newt (Taricha granulosa). This receptor is
believed to be a G-protein coupled receptor because corticosterone binding is inhibited
by guanyl nucleotides and enhanced by Mg2+. The studies described in this thesis use
biochemical, pharmacological and molecular techniques to characterize the newt
neuronal membrane glucocorticoid receptor (mGR) in pursuit of its molecular
identification. The mGR was successfully solubilized from newt neuronal membranes
and conditions were defined that maintained corticosterone binding activity for further
study. The solubilized receptor was partially purified using standard chromatographic
techniques and an immobilized ligand affinity resin (CORT-Sepharose). These
chromatographic studies were combined with the use of a novel photoaffinity ligand
(azido-CORT) to biochemically characterize the mGR protein, finding that it is an
acidic glycoprotein with an apparent molecular weight of 63 kDa and an isoelectric
point of approximately 5.0. Pharmacological studies with mGR showed that a subset
of kappa opioid ligands displaced corticosterone from the receptor binding site with K1
values in the nanomolar to low-micromolar range. The interaction of mGR with kappa
opioid ligands was specific because no mu-, delta-, or orphanin-specific opioid ligands
were effective at displacing corticosterone from the receptor. These data suggest that
the newt neuronal mGR may be a kappa-opioid like receptor. Finally, molecularstudies were used to clone a novel newt brain protein, neuronal axonal protein 22 
(NAP-22), that was identified in a protein differential display strategy designed to 
identify mGR. Studies with the cloned and expressed NAP-22 protein suggest that it is 
not the mGR but, instead, may be a mGR-associated protein. These studies provided 
new information about the biochemical and pharmacological properties of mGR, and 
may have discovered a protein that is associated with the newt neuronal mGR. Copyright by Simon J. Evans
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Chapter 1 
Genomic and Nongenomic Models for Steroid Hormone Action:
 
Historical Perspectives and Experimental Evidence
 
1.1 Introduction to Glucocorticoids 
Glucocorticoids are a class of steroid hormones that are essential for most forms of 
animal life. This class of hormone is required for normal function of the nervous 
system, immune system, and cardiovascular system, normal maintenance of skeletal 
muscle and bones, and normalization of blood sugar balance (1). In addition to these 
"permissive" effects, glucocorticoids are also a major component of the stress 
response. When a threat is perceived, either physical or emotional, the hypothalamus 
instructs the pituitary gland to release adrenocorticotropin (ACTH), which in turn 
instructs the adrenal glands to release glucocorticoids (1,2). This can lead to the acute 
effects of immunosuppression, mobilization of energy stores to the muscles, increase 
of pulmonary and cardiovascular tone, a stress-induced analgesia, and even cognitive 
alterations that can sharpen sensory thresholds (1,3). 
Activation of the hypothalamic-pituitary-adrenal (HPA) axis is kept in check by 
feedback to the brain from glucocorticoids themselves. Escape from this feedback 
inhibition is correlated with some types of severe clinical depression (4). Several other 
disease states can also stem from glucocorticoid disorders. Addison's disease is an 
insufficiency in glucocorticoid release from the adrenal glands and is characterized by 
weakness, abnormal pigmentation of the skin, weight loss, low blood pressure, and 
gastrointestinal  upset  (1,2).  Cushing's syndrome stems from an excess  of 
glucocorticoids and can involve obesity of the trunk and face, muscle wasting, high 
blood pressure, increased skin bruisability, osteoporosis, and diabetes mellitus (1,2). 2 
These effects of glucocorticoid imbalances underscore the importance of this hormone 
class in the regulation of physiology and homeostasis. 
With the involvement of glucocorticoids in so many physiological processes it follows 
that they also have significant clinical value. The glucocorticoid endogenous to 
humans, cortisol, was first isolated from adrenal cortex in 1935 by Kendall and later 
used by Hench in 1949 for the successful treatment of rheumatoid arthritis. These 
men, along with Reichstein, received the Nobel Prize for Physiology or Medicine in 
1950 for this work. Since this time glucocorticoids have been used in the treatment of 
many diseases, most notably as anti-inflammatory or immunosuppressive agents (1). 
In fact, today glucocorticoids are among the most heavily prescribed drugs within 
Western society pharmacopoeia. 
1.2 Historical Perspectives 
With the discovery of glucocorticoids by Kendall, questions into their mechanism of 
action could be addressed along with that of other known steroids. It was the 
production of radiolabeled estrogen by Jenson in 1958 that really provided a necessary 
tool for these types of studies. With this, the fate of a physiological dose of a steroid 
hormone could finally be monitored. Studies with estrogen thus provided the first 
insights into the mechanisms of steroid hormone action. Estrogen "receptors" or 
"estrophiles" were soon proposed and localized to nuclear and cytosolic fractions (5). 
Early work by Bellamy in 1962 used radiolabeled cortisol to trace this glucocorticoid 
in liver fractions (6), but it was Hollander and Chiu in 1966 (7) and Munck and 
Brinck-Johnsen in 1968 (8) who really described an intracellular glucocorticoid 
receptor with physiological activity. From this point, it took another two decades of 
study and purification attempts before Miesfeld, et al elucidated the first primary 
structure of a steroid receptor, the glucocorticoid receptor, in 1984 (9). 
Intracellular receptors for all the major steroid hormones have now been cloned and 
these continue to be the subject of intense investigation. The discovery of these 3 
receptors and their characterization has lead to the "genomic model" of steroid 
hormone action. In this model, steroids cross the plasma membrane due to their 
lipophilic nature and gain access to intracellular receptors. Upon binding of the steroid 
to its receptor, the complex undergoes translocation to the nucleus (if not already in 
the nucleus) where it recognizes specific cis-acting response elements in the promoter 
regions of target genes to modulate their transcriptional  activity. This is an 
oversimplified account, as there is ligand-independent activity of some steroid 
receptors and interactions with other proteins. However this remains the basic model 
by which steroids are known to act. This model can explain many of the effects of 
steroid hormones and is the subject of several review articles (10.-13) and textbooks 
(14-16). 
Simultaneous to the work being done to characterize these intracellular steroid 
receptors, other studies with steroid hormones, although much fewer in number, were 
producing observations that were inconsistent with the developing genomic model. 
These were mostly studies that observed responses to steroids that were too rapid to be 
accounted for by the relatively slow process of transcriptional regulation; or responses 
to steroids in isolated membrane fractions that presumably lacked intracellular 
receptors. Perhaps the earliest account of such observations was by Seyle in 1942 with 
the description of rapid anesthetic effects by progesterone (17). In 1971 Smith and 
Ecker proposed that progesterone might have activity at the cell surface of oocytes 
from the northern leopard frog (Rana pipiens) (18). In 1974 Edwardson and Bennett 
observed membrane actions of glucocorticoids  in modulating the release of 
corticotropin-releasing factor (CU) from hypothalamic synaptosomes (19), and in 
1975 Neckers and Sze reported a rapid effect of corticosterone on tryptophan uptake in 
synaptosomal membranes (20). Also in 1975, Pietras and Szego demonstrated that 
estrogen could have rapid effects with studies on calcium flux in endometrial cells 
(21). Beulieu was perhaps the most notable early proponent of a non-genomic action 
of steroid hormones with a review in 1978 extrapolating his work with steroid 
membrane effects in oocytes to a wider significance of membrane actions for steroid 
hormones (22). These reports and others lead to the hypothesis that steroids exert 4 
some effects through non-genomic mechanisms, initiating responses at the level of the 
cell membrane. 
Even though these membrane effects of steroids were being reported, the discovery of 
intracellular steroid receptors in the mid-1960's and the momentum produced by the 
number of studies working on the premise of the genomic model, overshadowed the 
few studies observing non-genomic effects of steroid hormones. By the mid-1970's 
the scientific community had almost exclusively accepted the genomic model as the 
explanation of steroid hormone action. This had the effect of not only directing most 
of the attention toward the genomic model, but also diverting most of the resources 
and funding opportunities to support these studies as well. Nonetheless, studies of 
non-genomic mechanisms of steroid hormone action continued and eventually gained 
some momentum of their own. 
The past two decades have seen many reports on non-genomic effects of steroid 
hormones. These effects can be broken down into two types of basic actions. First, 
steroids can act by intercalating into lipid membranes to induce physiochemical 
changes in membrane properties (23) or changes within the microenvironment of 
membrane proteins. These effects can be specific in that not all steroids will induce the 
same changes, however they usually require high concentrations of the steroid 
hormone. An example of this is that progesterone can effect sperm membrane fluidity 
and vesicular membrane fusion that is not mimicked by estradiol or testosterone (24). 
Second, steroids can interact specifically with membrane bound receptors to modulate 
their activity, either directly or in response to another hormone. These interactions 
with membrane receptors influence specific cellular processes that contribute to the 
physiological roles of steroid hormones. An understanding of these membrane 
receptors is critical for a complete understanding of steroid hormone action. It is 
evidence for these physiologically relevant membrane steroid receptors (recently 
reviewed by Wehling, 1997; Moore and Evans, 1999) that will be the focus of the 
remainder of this introduction. Studies with a specific glucocorticoid membrane receptor in the brain of the roughskin newt (Taricha granulosa) will be the focus of 
the remaining chapters in this thesis. 
1.3 Experimental Evidence for Membrane Steroid Receptors 
For the remaining sections in this introduction, the evidence for membrane steroid 
receptors will be grouped by steroid class (i.e. progestins, estrogens, androgens, 
corticosteroids, and vitamin D). 
1.3.1 Progestins 
The evidence for membrane actions of progesterone and its metabolites is unique 
relative to that of other steroids because two known receptors have convincingly been 
shown to be directly modulated by this class of steroids. In 1986 Majewska showed 
that specific progesterone metabolites could increase binding of benzodiazepines to 
the GABAA receptor and potentiate the inhibitory actions of GABA in cultured 
hippocampal neurons (25). These data were intriguing because they provided a 
mechanism for the known analgesic properties of progesterone. The action of 
progestins at the GABAA receptor has since been intensively studied and is the subject 
of several reviews (26-31). In 1990 Schumacher reported a rapid increase in oxytocin 
receptor binding in response to progesterone in the ventromedial nuclei of the 
hypothalamus and suggested that this was caused by a direct action of progesterone at 
the oxytocin receptor (32). Since oxytocin is known to promote lordosis behavior 
these data provided a potential explanation for the rapid effects of progesterone on this 
behavior.  In 1998 Grazzini showed that progesterone can bind to the oxytocin 
receptor in rat endometrial cells and inhibit its response to oxytocin (33). These data 
are consistent with the antagonistic relationship between progesterone and oxytocin in 
the control of pregnancy and parturition. 6 
A novel putative progesterone receptor has been purified (34) and cloned (35) from 
porcine liver membranes, however binding activity has not been reconstituted in vitro. 
This protein is predicted to possess a single transmembrane domain and is not 
significantly related to any other known protein. Photo labeling of this receptor 
identified two bands on SDS-PAGE that were reduced to a single band in a native gel, 
suggesting that the active receptor is a heterodimer (36,37). This might explain the 
inability to reconstitute binding in vitro from a single transcript. Using a peptide 
specific antibody this receptor was localized to endomembranes in both cultured 
hepatocytes and transfected HEK cells (38). Interestingly, using radioligand binding 
assays this receptor was shown to have high affinity for sigma receptor ligands and 
may thus be a member of the sigma receptor family (39). 
Progestins have also been shown to mediate rapid effects in sperm that appear to be 
conducted through membrane receptors. Progesterone can rapidly initiate Cr efflux 
through a GABAA-like receptor that is reversed by the GABA antagonists picrotoxin 
and bicuculline (40). Progesterone can rapidly initiate Ca2+ influx (41) and tyrosine 
phosphorylation (42) in sperm cells, which are actions that appear to be mediated by 
two different receptors (43). The effect on Ca2+ uptake can be mimicked by 
progesterone that has been conjugated to BSA to prevent entry to the cell, providing 
further support for the involvement of a membrane receptor (44,45). These events are 
all involved in the sperm acrosome reaction which is required for fertilization. In fact, 
an inability of sperm cells to respond to the progesterone-induced acrosome reaction 
has been correlated with some types of male infertility (46). 
Progesterone has been known for some time to play a major role in oocyte maturation 
(47). Some of the effects induced by progesterone in these cells seem to be mediated 
by membrane receptors. An increase in intracellular free Ca2+, associated with oocyte 
maturation, occurs within 40-60 seconds upon exposure to progesterone (48). 
Increases in cytosolic inositol triphosphate (IP3) and diacylglycerol (DAG) are also 
seen in less than 15 minutes of progesterone exposure (49). A 110 kDa protein, 
associated with the inhibition of adenylate cyclase and germinal vesicle breakdown 7 
(50), has been identified in oocyte membrane preparations using  a photoactive 
progesterone derivative (51,52). Independent studies have also identified specific 
progesterone binding sites in these cells, which play a role in meiotic cell division 
(53). 
1.3.2 Estrogens 
The evidence for membrane estrogen receptors is also significant. Stimulation of the 
hypothalamic-pituitary-gonadal (HPG)  axis  begins  with GnRH release  from 
hypothalamic neurons and culminates in the release of 1713 estradiol (E2) from 
gonadal cells (1). E2 can then provide negative feedback within 30 minutes to inhibit 
further GnRH release (54). As a potential mechanism for this feedback, E2 has been 
shown to rapidly hyperpolarize hypothalamic GnRH neurons by activation of an 
inward rectifying potassium channel (55). This channel may be involved in GnRH 
release as a convergence point for mu-opioid receptors, GABAB receptors, and a 
membrane estrogen receptor in GnRH cells (54,56,57). 
Rapid modulation of kainate-induced currents in hippocampal CA1 neurons (58) and 
Ca2+ currents in neostriatal  neurons (59) by estrogen have also been shown. These 
latter two effects seem to be mediated by a G-protein coupled mechanism because 
they can be attenuated by the presence of guanyl nucleotides. In addition to these 
electrophysiological studies, pharmacological experiments also provide evidence for 
membrane estrogen receptors in brain with the identification of specific estrogen 
binding sites in pituitary (60,61). 
Rapid estrogen effects are also seen in reproductive tissues. Estrogen increases 
intracellular calcium concentrations in granulosa cells (62) within a few seconds of 
application. This rapid increase in intracellular calcium is not sensitive to removal of 
calcium from the cell media or inhibition of calcium currents, but is reversed by 
phospholipase C (PLC) inhibitors. This suggests that release of calcium from 8 
intracellular stores by IP3 is responsible. Such increases in intracellular calcium are 
suggested to be important for intraovarian cell-cell communication (63). A rapid 
estrogen effect on calcium influx, which is sensitive to removal of calcium from the 
cell media, is also seen in oocytes (64). This effect can be mimicked by estradiol 
conjugated to BSA, excluding the genomic model as an explanation (64). Within 10 
minutes, endometrial cells can also increase calcium uptake in response to estrogen 
(65), and binding studies provide support for the existence of membrane estrogen 
receptors in these cells (66). 
E2 has also been shown to bind to the membrane protein ErbB2 with high affinity 
(67). This protein is a protooncogene product related to the epidermal growth factor 
(EGF) receptor and has been shown to play a role in some types of breast cancer 
(68,69). Binding of E2 to ErbB2 stimulates its tyrosine kinase activity and induces 
autophosphorylation, suggesting that ErbB2 may be a membrane estrogen receptor. 
Given the many roles estrogens have in breast cancer (70,71) these data are interesting 
and may provide some important explanations about estrogenic effects. 
1.3.3 Androgens 
The literature describing specific membrane actions of androgens is  far less 
voluminous than that of other steroids, however examples do exist. In Sertoli cells 
testosterone (T) can induce rapid Ca2+ influx that can be mimicked by T conjugated to 
BSA to prevent cellular entry (72). These data may partially explain the synergistic 
actions of T and follicle stimulating hormone (FSH) on Sertoli cells in support of 
spermatogenesis (73). In bone, sub-nanomolar concentrations of T can increase 
intracellular calcium as well as inositol triphosphate (IP3) and diacylaglycerol (DAG) 
formation. These effects occur within seconds of T application and can be abolished 
by pertussis toxin, suggesting the involvement of a G-protein coupled mechanism 
(74). 9 
1.3.4 Vitamin D3 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) rapidly increases calcium transport across 
chick duodenal membranes (75). This transport is unidirectional, from the lumen to 
the vascular effluent, and occurs at physiological concentrations of the steroid 
hormone (76). This process is likely to be mediated by a nongenomic action of vitamin 
D3 for several reasons. First, the time scale is too rapid too be accounted for by the 
genomic model. Second, the pharmacological profile of the response to vitamin D3 
congeners is inconsistent with the pharmacological profile of the intracellular vitamin 
D3 receptor (77). Third, vitamin D3 congeners that effect rapid calcium transport can 
induce tyrosine-phosphorylation of mitogen activated protein (MAP) kinase with 30 
seconds of steroid exposure (78). Finally, a 1,25(OH)2D3 binding protein has been 
purified from chick intestinal basolateral membranes. The KD of 1,25(OH)2D3 for this 
"receptor" is within the physiological concentration of the steroid and within the 
concentrations that induce the rapid calcium transport effect. 
The involvement of vitamin D3 in bone growth and remodeling appear to involve both 
genomic and nongenomic actions of this steroid hormone. Genomic actions of vitamin 
D3 play an important role in bone cell differentiation (79,80). This process may also 
involve nongenomic actions of this steroid because a membrane binding site for 
vitamin D3 metabolites has been described in bone cell progenitors (81,82). 
Nongenomic actions of vitamin D3 have also been shown to effect CF currents in 
mature osteoblasts (83). 
1.3.5 Mineralocorticoids 
Consistent with its role in regulation of Na+ levels, aldosterone has been shown to 
rapidly increase the activity of the Na±/H+ exchanger in human mononuclear 
leukocytes (HML) (84) and vascular smooth muscle (VSM) cells (85). Both of these 
responses are insensitive to cortisol, providing an aldosterone specific signalling 10 
pathway. This is significant because the intracellular mineralocorticoid receptor is 
responsive to glucocorticoids. The aldosterone stimulation of the Na+/H+ exchanger in 
HML cells has been shown to involve the generation of IP3 in response to sub­
nanomolar concentrations of the steroid (86). Furthermore, membrane binding sites for 
aldosterone in this cell type have been described and have a KD of 0.1nM, equal to the 
ECK, for the generation of IP3 in these same cells (87). This strongly suggests that this 
membrane binding site is involved in the rapid effect of aldosterone on IP3 generation. 
Using an [125I]aldosterone derivative a 50 kDa protein was identified in HML 
membranes as a putative aldosterone membrane receptor (88). In VSM cells, the 
aldosterone effect on sodium transport also uses IP3, as well as DAG, phospholipase C 
(PLC), and protein kinase C (PKC). In these cells, aldosterone exposure increases 
DAG production within 30 seconds and activates PKC within 5 min. These studies 
provide strong support for the existence of a membrane aldosterone receptor that uses 
classical signal transduction machinery in response to physiological concentrations of 
this steroid hormone. 
1.3.6 Glucocorticoids 
Neurophysiological studies have shown rapid glucocorticoid effects in neurons from 
the hippocampal CA1 region (89), locus coeruleus (90), reticular formation (91), 
coeliac ganglion neurons (92) and medullary neurons (93,94). In hippocampal CA1 
neurons the inhibition of Ca2+ currents by cortisol seems to be mediated by N-type and 
L-type calcium channels. The cortisol effects are reversed by treatment with pertussis 
toxin or dialysis of GDPI3S, suggesting the involvement of a G-protein coupled 
signalling mechanism (89).  In  coeliac  ganglion neurons glucocorticoids  can 
hyperpolarize the membrane potential and this effect can by mimicked when the 
steroid is conjugated to BSA to prevent cellular entry (92), suggesting the involvement 
of a membrane receptor. 11 
In addition to neurophysiological studies, membrane binding sites for glucocorticoids 
have been described in various tissues including, liver (95-101) lymphocytes (102­
108), adrenal cortex (109), thymocytes (110), and brain (111-113). Interestingly,  a 
membrane glucocorticoid receptor in lymphocytes is recognized by antibodies directed 
at epitopes on the  intracellular glucocorticoid receptor (iGR) (103,107). The 
membrane and intracellular receptors in these cells appear to be distinct, because of 
different migrations on SDS-PAGE (106). However, their common immunoreactivity 
suggests that these two proteins may be related. The membrane form of GR appears to 
play a role in the lytic response of lymphoma cells to glucocorticoids (103,108). 
1.3.7 A newt neuronal membrane glucocorticoid receptor 
A membrane glucocorticoid receptor (mGR) has previously been described in brains 
of  the  roughskin  newt  (Taricha  granulosa)  using  neurophysiological, 
pharmacological, biochemical and behavioral  studies. Non-genomic actions of 
glucocorticoids in this animal were first suspected with the observation that either 
stress or systemic injections of corticosterone rapidly inhibit sex behavior in male 
newts (114). With the use of radioligand binding assays, a high affinity (KD = 0.5nM), 
saturable corticosterone binding site was identified in membrane preparations from 
newt brains. Sub-cellular fractionation studies localized this binding site to neuronal 
plasma membranes (113) and binding of corticosterone to this site is destroyed by 
either heat or proteolysis, suggesting it is a protein (113). The affinities of various 
steroids for this binding site correlate with their potency to inhibit newt sex behavior, 
providing strong evidence that this receptor is involved in the control of sex behavior 
in this animal. The newt neuronal mGR has characteristics of a G-protein coupled 
receptor in that binding of corticosterone is inhibited by the presence of guanyl 
nucleotides and enhanced by the presence of Mg2+ (115). Neurophysiological studies 
support the hypothesis that corticosterone is acting through a neuronal membrane 
receptor, mainly because corticosterone exerts rapid effects on the activity of 
medullary neurons in male newts (93,94). 12 
In addition to these data, the pharmacological profile of mGR suggests it is distinct 
from iGR. The high affinity iGR agonist dexamethasone is unable to displace 
[3H]corticosterone from the membrane site (113), has no acute effect in behavioral 
assays (113), and is unable to rapidly modulate the neurophysiological effects of 
corticosterone (93). Some species have iGRs that are insensitive to dexamethasone, a 
property that has been attributed to a single amino acid substitution in the hormone 
binding domain of the iGR protein (116). Sequencing of partial newt iGR cDNA 
clones suggests that newt iGR is dexamethasone sensitive (Carla Richardson, 
unpublished data). Furthermore, dexamethasone can modulate the CORT effect on 
neurophysiology in newt brain through a slow, presumably genomic mechanism (93), 
providing further evidence that newt iGR responds to dexamethasone. Therefore, the 
insensitivity  of newt mGR, and the  predicted  sensitivity  of newt iGR to 
dexamethasone, support the hypothesis that these two proteins are distinct. Taken 
together, the rapid effects of corticosterone on behavior and neurophysiology, the 
localization of a high affinity corticosterone binding site to membrane fractions, the G-
protein coupled receptor characteristics of this binding site, and the pharmacological 
distinctions from the intracellular glucocorticoid receptor, these data provide strong 
evidence that newt brains possess a membrane receptor for corticosterone. 
Evidence is also available that a membrane corticosterone receptor exists in rats 
brains, primarily due to corticosterone binding data (117). The larger brain of a rat as 
compared to a newt (approximately 1:100 by mass) would provide significant 
advantages in a project directed at identifying mGR via a protein purification strategy. 
However, the newt neuronal mGR was selected as the subject for the studies described 
in this thesis for several reasons. First, the affinity of [3H]CORT for the newt mGR is 
approximately 0.5nM (113) as compared to approximately 100nM for the rat 
membrane CORT receptor (117). Second, the specific binding of [3H]CORT in newt 
neuronal membrane preparations at it's KD is about 85% (113) compared to about 25% 
in rat neuronal membrane preparations (117). These provided technical advantages to 
working with newt brain tissue. Third, studies of the newt mGR are much broader than 
those of the rat neuronal membrane CORT receptor. For example, the evidence that 13 
the newt mGR is  a G-protein coupled receptor provided insights that were 
advantageous in the design of experimental strategies. The focus of the remaining 
chapters of this thesis will describe studies directed at elucidating the molecular 
identity of the newt neuronal mGR. 
Chapters 2 and 3 discuss studies using novel and standard biochemical techniques that 
had the aim of obtaining partial amino acid sequence information from purified mGR 
protein. Although the end-point of this objective was not reached, insights into the 
biochemical properties of the mGR protein were revealed and specific biochemical 
tools are described that could facilitate future success in this endeavor. Chapter 4 
discusses studies that use phamacological techniques that had the aim of relating mGR 
to a known hormone system. These revealed interesting pharmacological properties of 
the receptor that suggest a role for mGR in a broader endocrine context. Chapter 5 
describes the molecular cloning and expression of a novel newt brain protein 
identified as a candidate membrane corticosterone receptor. Although, the hypothesis 
that this protein is mGR was rejected, a possible relationship to mGR was explored. 
Finally, Chapter 6 summarizes the objectives and results of this thesis. 
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2.1 Abstract 
In addition to the classical nuclear action of steroids, membrane receptors are also 
involved in the physiological roles of this hormone class.  We report the 
pharmacological characterization of a solubilized corticosterone receptor from newt 
(Taricha granulosa) neuronal membranes.  This receptor previously was shown to 
localize with plasma membrane subcellular fractions and to be involved in modulation 
of courtship behavior in the male newt. We describe procedures with non-ionic 
detergents that solubilize the receptor and maintain high affinity [3H]corticosterone 
binding. The pharmacology of the solubilized corticosterone receptor resembles that 
of the membrane receptor with high affinity for [3H]corticosterone and an identical 
rank order potency of corticosterone > cortisol > aldosterone > dexamethasone for 
these other steroid ligands.  Unlike the membrane bound form, [3H]corticosterone 
binding to the solubilized receptor is insensitive to modulation by guanyl nucleotides 
and only modestly sensitive to the presence of Mg'. We also report the identification 
of ligands which will prove useful in an affinity purification scheme. Two novel 
ligands are shown to be active  at the  solubilized receptor:  corticosterone-3­
carboxymethyloxime (CORT- 3 -CMO), which may be covalently attached to a 
Sepharose resin, and a derivitized azide form of this ligand which can be covalently 
coupled to the solubilized receptor itself. The solubilized [3H]corticosterone receptor 
is stable in the detergent system which will facilitate further purification and molecular 
characterization. 
2.2 Introduction 
Steroid hormones are known to use intracellular receptors that bind DNA in a 
sequence specific manner to modulate transcriptional activity of target genes. 
Evidence for another mechanism of action using plasma membrane receptors has 23 
accumulated over recent years (review by Wehling, 1997)(1) and  comes from 
pharmacological, electrophysiological and behavioral experiments. 
Progestins (2,3), glucocorticoids (4-6), estrogens (7), mineralocorticoids (8,9) and 
vitamin D3 (10) have all been shown to bind specifically to cellular membrane sites. 
Rapid influences on electrolyte movement across cellular membranes are also induced 
by progesterone (11), glucocorticoids (12,13), estradiol (14,15), aldosterone (8), 
Vitamin D3 (16) and testosterone (17). Rapid behavioral effects of corticosterone are 
shown in the modulation of mating behavior of male newts (4,18). 
There is also evidence that implicates the involvement of G-proteins in the signal 
transduction machinery of some steroid membrane receptors.  Cortisol-induced 
inhibition of Ce currents in guinea pig is diminished by pertussis toxin treatment or 
the presence of GDPPS (12). Corticosterone binding in newt brains is inhibited by 
guanyl nucleotide analogs in a concentration dependent manner (19). Aldosterone 
effects on HML cells involve 1,4,5-inositol trisphosphate and are sensitive to pertussis 
toxin but not to cholera toxin (8).  Estradiol inhibition of Ca2+ currents in rat 
neostriatal neurons is reversed by GTPyS (15).  Testosterone stimulation of Ca2+ 
currents and formation of 1P3 and DAG in rat osteoblasts is blocked by pertussis toxin 
(17). All of these observations are both consistent with and characteristic of G-protein 
coupled signal transduction mechanisms. 
A receptor for corticosterone found in newt (Taricha granulosa) neuronal membranes 
has previously been identified and characterized (4).  This protein possesses 
characteristics of a G-protein coupled receptor (19) and plays a role in specific 
behaviors of the male newt. A single intraperitoneal injection of corticosterone 
inhibits courtship behavior with a latency of less than 8 minutes (4) and inhibits stress-
induced locomotion in a similar time frame (20). The affinities of an array of steroids 
for this [3H]corticosterone binding site are correlated with their respective potencies in 
newt behavioral assays (4). The receptor is enriched in plasma membrane fractions 24 
prepared by sucrose density centrifugation and does not bind select ligands which have 
high affinity for intracellular glucocorticoid receptors (4).  These data suggest that 
there is a membrane corticosterone receptor which is distinct from the intracellular 
corticosterone receptor. 
Detergent solubilization followed by affinity purification of membrane receptors has 
proven useful in advancing molecular and biochemical understanding of various 
receptor systems. We have extended the work with the newt corticosterone membrane 
receptor by solubilizing the receptor from newt brains using non-ionic detergents and 
have characterized it in this form. We have also identified ligands that can be used 
during affinity purification. 
2.3 Materials and Methods 
Male T granulosa were collected locally and used immediately or stored in tanks 
containing de-chlorinated water for up to three weeks.  Stored animals were feed 
tubifix worms on a three day cycle. 
[3H]corticosterone (71.07Ci/mmol) was purchased from NEN/Dupont (Boston, MA). 
Corticosterone, aldosterone, dexamethasone, digitonin, sodium cholate, bacitracin, 
trypsin inhibitor, dioxane and Sephadex were from Sigma Chemical Company (St. 
Louis, MO).  Corticosterone-3-carboxymethyloxime (CORT-3-CM0) was from 
Steraloids, Inc. (Wilton, NH). PMSF and leupeptin were from Boehringer Manheim 
(Indianapolis, IN). Sucrose was from Mallinkrodt (Paris, KY) HEPES from Research 
Organics, Inc (Cleveland, OH) and EDTA from JT Baker Co (Phillipsburg, NJ). N-(2­
aminoethyl)-4-azido-2-nitroaniline was purchased from Molecular Probes (Eugene, 
OR). 25 
2.3.1 Preparation of neuronal membranes 
Synaptosomes were prepared from newt brains by the method of Whittaker (21) with 
modifications by Orchinik et al. (22). Briefly, newt brains were homogenized in 40 
vol. (per original weight) 0.32M sucrose, 5mM HEPES, pH 7.45 using a Teflon on 
glass tissue homogenizer. Homogenate was centrifuged at 1,000 x g for 10 min. at 4°C 
using a Beckman J2-21 centrifuge.  Pellet (P1) was discarded and supernatant 
centrifuged at 16,000 x g. for 40 min. at 4°C. Pellet (P2) was quick frozen and held at 
-70°C for at least 30 min. then resuspended in 150 vol. (per original brain weight) 
25mM HEPES, 10mM EDTA, pH 7.45 and held at 4°C for 2-3 hours to allow the 
dissociation of any endogenous ligand. Suspension was centrifuged at 40,000 x g for 
15 min. at 4°C. Pellet was resuspended in 25mM HEPES, pH 7.45 for final wash and 
centrifuged again at 40,000 x g for 15 min. at 4°C. A protein analysis by the method 
of Lowry et al (23) was generally performed prior to the final spin. Pellets were stored 
at -70°C for at least 30 min. or until use. All above steps included a protease inhibitor 
cocktail consisting of PMSF (0.1mM), trypsin inhibitor (100µg/ml), leupeptin 
(0.71.1,g/m1) and bacitracin (10014m1). 
2.3.2 Solubilization of membrane receptor 
Receptor was solubilized by the method of Peterson and Schimerlik (24) with some 
modification. Pellets were resuspended to a protein concentration of 5mg/m1 in 25mM 
HEPES, pH 7.45.  To this suspension was added 0.25 vol. of 4% digitonin, 0.8% 
sodium cholate, 25mM HEPES, pH 7.45. Suspension was held at room temperature 
for 20 min. with occasional gentle mixing.  Suspension was ultracentrifuged at 
>100,000 x g using a Beckman L8-70M ultracentrifuge for 1 hr. at 2°C.  Pellet was 
discarded and membrane extract held at 0°C until use.  All steps included protease 
inhibitor cocktail as described above. 26 
2.3.3 Synthesis of photoaffinity ligand. 
Corticosterone-3-carboxymethyloxime  was  dissolved  in  30% dioxane  to  a 
concentration of 10mM.  N-(2-aminoethyl)-4-azido-2-nitroaniline was dissolved in 
30% dioxane to a concentration of 20mM. The two reagents were mixed together in 
equal volume then mixed with 0.1 volumes of 1M aqueous EDC. The reaction was 
incubated overnight at 4°C. The reaction mixture was extracted 3 times with equal 
volumes of ethyl acetate, aqueous phases were pooled and concentrated to dryness in a 
rotary speed-vac. Sample was resuspended in 60% acetonitrile/water and product 
purified from reactants over a C18 column with an isocratic gradient at 60% 
acetonitrile, collecting 0.5ml fractions. Fractions were dried as above and resuspended 
in 50111 60% acetonitrile for analysis by C18 thin layer chromatography.  Fractions 
containing pure product were pooled and identity was verified by mass spectral 
analysis. 
2.3.4 [3H]corticosterone binding to solubilized receptor 
All binding assays contained 801.il membrane extract, 0.1% ethanol (as ligand vehicle), 
25mM HEPES, pH 7.45 in a final volume of 2004 [3H]corticosterone was present at 
0.5nM and MgC12 at 10mM unless indicated otherwise. Binding reactions were held 
for 5-8 hours (unless indicated otherwise) at 30°C after which protein bound ligand 
was separated from free ligand by gravity filtration over G-50 Sephadex at 4°C, using 
binding assay buffer as the mobile phase. A protease inhibitor cocktail as described 
above was present throughout the binding assay. All experimental data were analyzed 
using Graph Pad Prism software (Graph Pad, Inc., San Diego, CA). 27 
2.4 Results 
2.4.1 [3H]corticosterone association and dissociation kinetics 
Kinetic experiments were performed to ensure that [31-1]corticosterone binding  was 
reversible and to establish parameters for subsequent equilibrium experiments (Fig. 
2.1).  The kinetic data were indicative of a simple bimolecular reaction with a 
monophasic association and dissociation. The half-time for equilibrium association at 
a 0.5nM radioligand concentration was 45 min. with a kobs of 0.015 ± 0.002 
Dissociation had a half-time of 60 minutes with a k1 of 0.012 ± 0.001 min.'. From 
these data a KD of approximately 2.0nM can be calculated which is in reasonable 
agreement with the affinity calculation from the saturation data (below). 
2.4.2 Equilibrium saturation analysis 
Saturation experiments were performed for an independent estimation of the affinity of 
[3H]corticosterone for the solubilized receptor and to determine the receptor specific 
activity (Fig. 2.2).  These data showed saturable, high affinity [3H]corticosterone 
binding to a homogenous population of receptors with a KD of 0.29 ± 0.02nM; in good 
agreement with previous reports for the membrane bound form (4). The B. value in 
this system was approximately 50 fmol/mg protein; similar to values found with the 
membrane bound receptor, suggesting no significant enrichment of specific activity. 
A Scatchard-Rosenthal plot of the data (Fig. 2.2, inset) was linear and therefore 
consistent with the labeling of a homogenous population of sites. The signal to noise 
ratio is unchanged by the solubilization procedure with approximately 80% specific 
binding at the KD. 28 
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Fig. 2.1.  Kinetics of 13H]corticosterone association and dissociation.  Binding 
conditions were as described in methods with reactions terminated at times indicated. 
The fits  for association and dissociation were generated using a single phase 
exponential association and a single phase exponential decay, respectively, with 
GraphPad Prism software.  Half-time of association at a 0.5nM radioligand 
concentration was 45 minutes with a kobs of 0.015 ± 0.002 min-1.  Dissociation half­
time was 60 minutes with a 1(1 of 0.012 ± 0.001 min-1. Data is representative of two 
independent experiments with duplicate time points. 29 
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Fig. 2.2. Equilibrium saturation analysis.  [3H]corticosterone concentration was 
varied over a 40-fold range as indicated under binding conditions described in 
methods.  Specific binding was calculated by subtracting non-specific binding, as 
defined in the presence of 101AM corticosterone, from total binding (not shown). The 
fit was generated assuming single site binding with Graph Pad Prism software. A KD 
of 0.29 ± 0.02nM and a B. of 50 fmol/mg protein were calculated from the data. 
Inset is a Scatchard-Rosenthal transformation of the saturation binding data. The line 
is a linear regression with r = 0.96 and gives a B.. estimate of 46 fmol/mg protein and 
an approximate KD of 0.24nM. Data is representative of two independent experiments 
with total binding determined from triplicate points and non-specific binding 
determined from duplicates. 30 
2.4.3 Equilibrium competition analysis 
To further evaluate the pharmacological signature of the solubilized [3H]corticosterone 
receptor, competition experiments were performed (Fig. 2.3). The rank order potency 
of the tested compounds is identical to previous reports (22) for the membrane 
receptor with the affinity of corticosterone > cortisol > aldosterone >> dexamethasone. 
This provides strong evidence that the receptor solubilized in this study is indeed the 
membrane corticosterone receptor identified previously.  In addition to these steroid 
ligands, two useful derivatives of corticosterone were evaluated for binding activity at 
the  [3H]corticosterone  receptor  (structures shown in  Fig.  2.3b).  The  first, 
corticosterone-3-carboxymethyloxime (CORT- 3 -CMO) has a free carboxyl group 
which can be coupled to the free amine of a solid support for the production of an 
affinity resin. The second, a photoactive derivative of CORT-3-CMO, CORT-azide, 
can be used as a photoaffinity label. Binding studies with this azide derivative were 
performed in the dark to minimize photoactivation during the incubation step. 
Corticosterone, cortisol, aldosterone, CORT -3 -CMO and CORT-azide completely 
inhibited specific [3H]corticosterone binding with Ki values of 0.24nM (95% C.I., 0.19 
to 0.30nM), 10.5nM (95% C.I., 7.5 to 14.5nM), 211nM (95% C.I., 175 to 255nM), 
2.6nM (95% C.I., 1.8 to 3.8nM) and 234nM (95% C.I., 135 to 402 nM) respectively. 
Dexamethasone only inhibited 15% of specific binding at a concentration of 1011M. 
The low affinity of dexamethasone suggests that the intracellular corticosterone 
receptor does not contribute to the [3H]corticosterone specific binding in the 
solubilized preparation. 
2.4.4 Lack of modulation of [3Hlcorticosterone binding by guanyl nucleotides 
The effects of guanyl nucleotides were examined because of previous reports showing 
significant negative modulation of [3H]corticosterone binding in the presence of these 
compounds  (Fig.  2.4).  GTPyS,  Gpp(NH)p, GDP  and GMP  inhibited 31 
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Fig. 2.3. Equilibrium competition analysis. 0.5nM [41]corticosterone binding was 
inhibited by increasing concentrations of various steroid hormones.  Corticosterone, 
cortisol, aldosterone and CORT-CMO completely inhibited specific [3H]corticosterone 
binding with Ki values of 0.24nM (95% C.I., 0.19 to 0.30nM), 10.5nM (95% C.I., 7.5 
to 14.5nM), 211nM (95% C.I., 175 to 255nM) and 2.6nM (95% C.I., 1.8 to 3.8nM), 
respectively. Dexamethasone, at 101.IM, only inhibited 15% of control binding. Data 
were analyzed assuming a single site competition model. Top values were constrained 
for all data sets, to the value observed in the absence of any competitor. Data was 
obtained from pooling two independent experiments. 32 
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Fig. 2.4. Lack of modulation of [3H]corticosterone binding by guanyl nucleotides. 
0.5nM [3H]corticosterone binding was measured in the presence of increasing 
concentrations of various guanyl nucleotides as indicated. With concentrations up to 
100i.tM no negative effect of guanyl nucleotides on [3H]corticosterone binding was 
observed.  Mg2+ was present at 1mM for all guanyl nucleotide  assays. Data are 
representative of three independent experiments for GTPyS and Gpp(NH)p and two 
experiments for GDP and GMP. 33 
[3H]corticosterone binding in membrane fractions by approximately 85%, 60%, 20% 
and 20%, respectively (19). We found no negative effect of these nucleotides  on 
[3H]corticosterone binding in the detergent solubilized system. A modest increase in 
[3H]corticosterone binding was observed in the presence of 1001A.M GDP. 
2.4.5 Modulation of [3H]corticosterone binding by Mg" 
To further assess the solubilized receptor with regards to characteristics typical of G-
protein coupled receptors, we evaluated the effect of the divalent cation, Mg', on 
[3H]corticosterone binding (Fig. 2.5).  Mg' typically stabilizes the receptor high 
affinity  state of G-protein coupled receptors by promoting G-protein-receptor 
interaction. The presence of Mg" in the detergent extract nominally increased binding 
by approximately 15% at a concentration of 3mM. This is in contrast to a 50% 
increase observed in the membrane receptor (19) and is consistent with the loss of 
guanyl nucleotide sensitivity. 
2.5 Discussion 
We have described the pharmacological characterization of a corticosterone membrane 
receptor solubilized from newt neuronal membranes.  This receptor has previously 
been pharmacologically (22) and physiologically (25) characterized and shown to be 
highly enriched in plasma membrane fractions using sucrose density gradient 
centrifugation (4).  There is a strong correlation between pharmacological and 
physiological characteristics of the membrane corticosterone receptor with IC50' s for 
[3H]corticosterone binding, correlated with EC50's in behavioral assays for an array of 
steroid ligands (4).  The localization of corticosterone binding sites to the plasma 
membrane, the lack of affinity for known intracellular glucocorticoid receptor ligands 34 
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Fig. 2.5. Effect of Mg2+ on [3H]corticosterone binding. Mg' was added to binding 
assay tubes as MgC12 to final concentrations indicated. A 15% increase in specific 
[31-1]corticosterone binding was observed with an ECK, of approximately 10gM and a 
maximal effect occurring by 3mM. Fit was generated using GraphPad Prism single 
site binding. Data are representative of two independent experiments. 35 
and the rapid behavioral effects of receptor binding, all provide strong evidence for a 
plasma membrane corticosterone receptor with physiological significance. 
Evidence for involvement of G-protein coupled signalling pathways exists for many 
steroid membrane actions.  Characterization of the newt neuronal corticosterone 
membrane receptor found significant negative modulation of [3H]corticosterone 
binding by guanyl nucleotides (19). Cortisol inhibition of calcium currents in guinea 
pig hippocampal CA1 neurons is also mediated by a G-protein coupled mechanism 
(12). The loss of guanyl nucleotide sensitivity in a detergent solubilized system,  as 
reported here, has precedence.  Several receptors known to be members of the G-
protein coupled receptor superfamily have previously been detergent solubilized with 
disparate characteristics regarding maintenance of guanyl nucleotide sensitivity after 
solubilization.  Al (26) and Ala (27) adenosine receptors, muscarinic acetylcholine 
receptors (24,28) and a variety of dopamine receptors (29-31) have all been 
successfully co-solubilized with G-proteins; while glucagon-like peptide (GLP-1) 
receptors (32), angiotensin II receptors (33) and CRF receptors (34) have lost 
detectable G-protein association in a solubilization procedure. 
G-protein coupled receptors can exist in a state of either high or low affinity for their 
respective ligands. The high affinity state is promoted by interaction with G-proteins 
and the low affinity state achieved by uncoupling from G-proteins. The maintenance 
of high affinity [3H]corticosterone binding in the absence of guanyl nucleotide 
sensitivity in the detergent system is thus paradoxical but can be explained by two 
alternative hypotheses.  1) Receptor-G-protein interaction is lost in the detergent 
system but the receptor high affinity state is favored by the detergent environment. 2) 
Receptor-G-protein interaction is maintained in the detergent system but GTP-GDP 
exchange is inhibited by the detergent environment. The latter hypothesis is consistent 
with the present data showing a nominal increase in binding in the presence of either 
Mg" or GDP. Either excess Mg' or GDP could drive the association of a small 
population of uncoupled receptors towards G-protein coupling. This would increase 36 
the number of receptors in the high affinity state and thus increase observed  specific 
[3H]corticosterone binding. 
Steroid derivatives have been successfully used to photo-label and partially purify 
steroid binding proteins (35) (36). We have shown that this corticosterone membrane 
receptor can retain high affinity binding activity as a solubilized protein and may thus 
be purified by exploiting this property.  Furthermore, we have identified ligands, 
CORT-3-CMO, and CORT-azide which can be used in an affinity purification scheme. 
The receptor is stable with no significant loss of binding activity over a three week 
period when stored at 0°C. 
Evidence for membrane steroid receptors has been accumulating for nearly two 
decades and it has become difficult to dismiss these data as having no physiological 
relevance. Steroid hormones play an integral part in both homeostatic and behavioral 
processes and are of significant clinical value accordingly. An understanding of the 
broad scope of steroid signalling mechanisms is imperative for the design of improved 
therapeutic agents which might discern between the divergent modes of steroid 
hormone action. Cloning and expression of membrane steroid receptor proteins will 
provide an opportunity for detailed systematic research into their molecular nature and 
physiological significance. 
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3.1 Abstract 
A membrane receptor for corticosterone (mGR) in the brain of the roughskin newt 
(Taricha granulosa) has been previously identified. This manuscript reports the 
evaluation of several chromatographic resins for enrichment of the newt mGR, 
solubilized from neuronal membranes. A protein with an apparent molecular weight of 
63 kDa was purified to near homogeneity following sequential purification using 
ammonium  sulfate  fractionation,  wheat  germ  agglutinin  (WGA)-agarose 
chromatography, hydroxylapatite chromatography, and an immobilized ligand affinity 
resin (corticosterone-Sepharose). In addition, a novel protein differential display 
strategy and a photoaffinity labeling strategy were employed to visualize candidate 
receptor proteins following SDS-PAGE. Both of these techniques also identified a 63 
kDa protein, agreeing with the purification data. Furthermore, the use of 2D SDS­
PAGE following the photolabeling procedure showed the candidate 63 kDa protein to 
have a pI of approximately 5.0. Taken together these data suggest that the newt mGR 
is an acidic glycoprotein with an apparent molecular weight of 63 kDa. Because these 
characteristics of the putative mGR are inconsistent with the characteristics of the 
intracellular glucocorticoid receptor, these two receptor proteins are apparently 
distinct. These studies also identified techniques useful in the purification of the newt 
mGR and provided information regarding the biochemical properties of the receptor. 
3.2 Introduction 
Many mechanisms of steroid hormone action remain elusive. The classical model for 
steroid action relies on the interaction of the steroid with an intracellular receptor that 
modulates transcriptional activity of target genes. This signaling route for steroids is 
well-characterized and can account for many of the known effects of steroid 
hormones. However, some responses to steroids are inconsistent with this model, and 
mounting evidence indicates that steroids can also interact with membrane receptors. 
These non-classical receptors for steroid hormones are the subject of several recent 
reviews (1-7). The evidence for the existence of membrane steroid receptors comes 41 
from several types of observations: 1) Some effects of steroid hormones are too rapid 
to be explained by the classical model. Electrophysiological studies have been used to 
observe effects on membrane conductance within seconds of exposure to estradiol (8), 
progestins  (9)  and  corticosteroids  (10).  2)  Some effects  of steroids  have 
pharmacologies that differ from the intracellular receptors. The progesterone-induced 
acrosome reaction in sperm (11,12) and the modulation of second messenger systems 
by testosterone in osteoblasts (13) have pharmacological profiles inconsistent with the 
classical receptors. 3) Steroids can induce effects when conjugated to BSA and thus 
prevented from entering the cell. Progesterone-BSA can modulate hypothalamic 
neuronal activity (14) and estrogen-BSA can potentiate kainate-induced currents in 
CAl neurons (15). 4) Some steroids have been shown to interact directly with known 
membrane receptors. Progesterone binds to the oxytocin receptor and inhibits oxytocin 
binding and oxytocin induced Cal' currents and inositol triphosphate (IP3) turnover 
(16). Progestin metabolites also directly modulate GABAA receptors (17). 
The evidence for a membrane corticosterone (CORT) receptor in brain comes from 
pharmacological,  behavioral  and  neurophysiological  studies.  A membrane 
glucocorticoid receptor (mGR) in brains of the roughskin newt (Taricha granulosa), 
an amphibian native to western Oregon, has been studied utilizing all of these 
techniques. Electrophysiological studies show that CORT has rapid effects on 
medullary neuronal activity in newts (18,19).  Studies with rats (10,20), guinea pig 
(21,22) and cats (23) also show rapid neurophysiological responses to glucocorticoids. 
Behavioral studies in newts show rapid inhibition of locomoter activity (24) and sex 
behavior by CORT (25,26). Effects of CORT on locomoter activity have also been 
observed in birds (27) and rats (28). Pharmacological studies show high affinity and 
specific binding sites for CORT in newt neuronal membranes (26). Studies using rat 
brains (29,30) and mouse pituitary (31) also observe specific CORT binding in 
membrane sites. Some of these membrane CORT effects, in addition to being of rapid 
onset, have a pharmacological profile inconsistent with the known type I (MR) and 
type II (GR) intracellular corticosteroid receptors. For example, the rapid effects of 
glucocorticoids on Ca2+ currents in guinea pig hippocampal CA1 neurons is sensitive 42 
to pertussis toxin (PTX) and GDPI3S, characteristic of a G-protein-coupled receptor. In 
newts, the rapid effect of CORT on neuronal activity (19) and behaviors (26) are not 
sensitive to the synthetic glucocorticoid, dexamethasone (DEX), nor is DEX able to 
displace [3H]corticosterone binding from plasma membrane sites (32). Furthermore 
this binding site is sensitive to modulation by guanyl nucleotides and Mg2+ (33), also 
characteristic of a G-protein coupled receptor. 
Detergent solubilization and chromatographic purification strategies have helped to 
identify several membrane steroid receptors and binding proteins. A receptor for 1 
alpha,25- dihydroxyvitamin D3 was solubilized and partially purified from chick 
intestinal epithelial membranes (34). This receptor has been shown to be involved in 
transport of Ca2+ across intestinal basal-lateral membranes (35). A membrane cortisol 
binding protein has been solubilized and purified from rat hepatic plasma membranes 
(36). The function of this protein is, to date, unknown. A putative progesterone 
receptor was solubilized, purified and partially sequenced from porcine liver 
membranes (37). This receptor was later cloned and appears to be a single 
transmembrane protein of 194 amino acids with little homology to any other known 
protein (38). Interestingly this progesterone membrane receptor is localized to 
endomembranes (39) and has a pharmacological profile reminiscent of sigma 
receptors (40). 
Another technique that has been used to identify steroid membrane receptors is the use 
of photoaffinity labels. Photoactive progestins have been used to label proteins in 
plasma membranes of Xenopus oocytes (41), mouse cerebellum (42) and porcine liver 
(43). Photoactive aldosterone derivatives have been used to label a protein in the 
plasma membrane of human mononuclear leukocytes  (44).  The photoactive 
glucocorticoid, dexamethasone mesylate, has been used to label membrane proteins 
from lymphocytes (45). These studies have provided information about apparent 
molecular weights of these putative membrane receptors and are thus useful in the 
design and evaluation of purification strategies. 43 
There are two primary advantages to working with the newt mGR. First, [3H]CORT 
has a sub-nanomolar affinity for the newt mGR with approximately 85% specific 
binding at its KD (26,46). In contrast, [3H]CORT binding studies in rat brain show a 
lower affinity of approximately 100nM with 70% specific binding (29,30). Second, 
the newt mGR is the only membrane glucocorticoid receptor for which both 
pharmacological and physiological data exist, as discussed above. The current study 
extends previous work, solubilizing the newt mGR (46), with purification techniques 
in combination with a photoaffinity labeling strategy to visualize the receptor on SDS­
PAGE gels. 
3.3 Materials and Methods 
All buffers, salts, detergents, DEAE-Sepharose, WGA-agarose and Donkey anti-Sheep 
IgG monoclonal antibody were purchased from Sigma Chemical Co. (St. Louis, MO). 
CM-Sepharose and EAH-Sepharose were from Pharmacia Biotech (Piscataway, NJ). 
Macro-Prep Ceramic hydroxylapatite resin and glass chromatography columns with 
flow adapters were from Bio-Rad (Hercules, CA). Disposable 2.5ml plastic 
chromatography columns were from IsoLabs (Akron, OH). Silver staining kit was 
from Novex (San Diego, CA). Anti-CORT antibody was from Cortex Biochemical 
(San Leandro, CA). Enhanced Chemiluminescence Super Signal Substrate was from 
Pierce (Rockford, IL). [3H]corticosterone (79 Ci /mmol) was purchased from New 
England Nuclear (Boston, MA). Roughskin newts (Taricha granulosa) were collected 
from local ponds and maintained in tanks containing continuously flowing de-
chlorinated water until used. Newts were fed tubifix worms on a 3-5 day cycle. 
Animals were treated in compliance with IAUAC standards and guidelines as 
approved by the Animal Use and Care Committee at Oregon State University. 44 
3.3.1 Stock solutions 
10X detergent:  4% digitonin, 0.8% sodium cholate, 25mM HEPES, pH 7.45 
Buffer A:  25mM HEPES, pH 7.45, 10mM MgC12, 1001.1M PMSF. 
Buffer B:  Buffer A with 0.8X detergent solution 
Buffer C:  Buffer B with 10mM MgC12 
3.3.2 Preparation of neuronal membranes 
P2 membrane pellets were prepared by the method of Whittaker (47) with  some 
modification. Newt brains were removed and resuspended in 1.2m1 of homogenization 
buffer (0.32M Sucrose, 5mM HEPES, pH 7.45, 100uM PMSF) per brain (--25mg wet 
weight) and homogenized with a teflon-on-glass tissue homogenizer. Homogenate was 
pelleted at 1,000 x g for 10 minutes at 4°C, and the resultant supernatant (S1) 
transferred to a clean centrifuge tube. Pellet (P1) was resuspended in homogenization 
buffer to original concentration and centrifuged again as above. Supernatant was 
pooled with S1 and spun at 30,000 x g for 40 minutes at 4°C. Pellet (P2) was quick 
frozen at 80°C then thawed on ice and resuspended in 4.5m1 per original brain 
number of 25mM HEPES, 10mM EDTA, pH 7.45, 10011M PMSF. Suspension of P2 
was incubated at 4°C for 2 hours to allow the dissociation of any endogenous ligand 
and centrifuged at 40,000 x g Resultant pellet was washed once with 25mM HEPES, 
pH 7.45 prior to freezing at 80°C. Pellets were either stored for up to several weeks at 
80°C or thawed on ice and used immediately. No loss of binding activity  was 
observed in stored pellets. 
3.3.3 Solubilization of membrane proteins 
Membrane proteins were solubilized by the method of Peterson and Shimerlik (48) 
with the modifications described previously (46). P2 pellets were resuspended in 45 
25mM HEPES, pH 7.45, 100[LM PMSF to a protein concentration of 5mg/ml. One-
quarter volume of 10X detergent was added to the suspension which  was then 
incubated at room temperature for 20 minutes with occasional gentle mixing. The 
suspension was centrifuged at 100,000 x g for 1 hour at 2°C. The resultant supernatant 
(membrane extract) contained solubilized proteins by definition and was used for all 
following experiments. 
3.3.4 Ammonium sulfate fractionation 
Ammonium sulfate was added directly to membrane extract to achieve concentrations 
given in the results section. Each precipitation step proceeded for 15 minutes on ice 
followed by a 5 minute centrifugation at 15,000 x g at 4°C. Supernatants were 
transferred to fresh centrifuge tubes for the next precipitation step and pellets were 
resuspended in buffer C for use in radioligand binding assays, total protein 
quantification or further purification. 
3.3.5 Preparation of chromatography columns 
Chromatographic resins were poured as  slurries into disposable 2.5ml plastic 
chromatography columns for hydroxylapatite and ion exchange resins, or glass 
columns with adjustable flow adapters for wheat-germ agglutinin agarose and 
corticosterone-Sepharose, and equilibrated with 10 volumes of buffer B prior to 
loading. For hydroxylapatite resin, the dry ceramic resin was resuspended as a 10% 
slurry in 0.1M potassium phosphate, pH 6.8 prior to equilibration with buffer B. 
Membrane extracts were diluted 2.5-fold with buffer A to achieve buffer B conditions 
prior to loading. All columns were loaded and run under gravity, with flow rates 
slowed to 0.5m1/min with an adjustable stopcock if necessary. Fractions of 0.5 ml 
were collected for binding assays and A280 readings. 46 
3.3.6 Synthesis of CORT-Sepharose 
EAH-Sepharose was washed with 80m1 of 0.5M NaC1 per 1 ml settled resin on a 
scintered glass filter followed by at least 10 volumes of distilled deionized water 
(ddH2O). Resin was drained and resuspended as a 50% slurry with 20mM 
corticosterone-3-carboxymethyloxime (CORT- 3 -CMO) in 30% dioxane, pH 4.5. One-
tenth volume of 1M N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) was added to catalyze the condensation reaction. Coupling was allowed to 
proceed overnight at 4°C on a gentle-rocking shaker. Resin was washed with 3 x 10 
volumes of 30% dioxane to remove excess ligand followed by alternate washes with 
0.5M NaC1, pH 9 and 0.5M NaC1, pH 4. Finally the resin was washed with ddH2O and 
drained prior to loading into glass chromatography columns. 
3.3.7 Radioligand binding assays 
[3H]CORT binding  assays were performed as previously described for membrane 
fractions (26) and solubilized fractions (46). Briefly, solubilized receptor radioligand 
binding assays contained 80111 membrane extract and 120p1 Buffer C for controls, to 
determine receptor binding activity in starting materials. Alternatively, 2001i1 of a 
chromatography fraction + 10mM MgC12 were used for the assays. [3H]corticosterone 
was present at a concentration of 0.5nM, near it's KD (26,46), and non-specific binding 
was defined in the presence of 10p,M corticosterone. Binding was allowed to reach 
equilibrium at 30°C over 4-6 hours and binding was terminated by separating bound 
ligand from free by filtration over a 2.5m1 G-50 Sephadex column at 4°C using buffer 
B as the mobile phase. For membrane binding assays, conditions were as above except 
100pg membrane protein were suspended in 300111 buffer C and reactions were 
terminated by rapid filtration over GF/C glass fiber filters equilibrated in cold assay 
buffer. CPM's were determined using a Beckman LS 6500 scintillation counter. 47 
3.3.8 SDS-PAGE
 
For 1 dimensional (1D) gels proteins were separated on SDS-PAGE gels as described 
by Laemm li (49) using a BioRad Mini Protean II electrophoresis system. For 2 
dimensional (2D) gels samples were resuspended in 125g1 IPG strip rehydration 
buffer (8M urea, 0.3% DTT, 1% triton X-100, 1% CHAPS, 2% ampholytes (3-10L, 
Pharmacia)) and used to rehydrate 7cm, 3-10L immobiline dry strips (Pharmacia) 
overnight. Proteins were focused using the Pharmacia Multiphor II system using a 
linear gradient program as follows: Step 1, 200V, 2mA, 7W, for lmin.; Step 2, 
3500V, 2mA, 7W, for 90 min.; Step 3, 3500V, 2mA, 7W, for 125 min. Focused IPG 
strips were incubated 10 min. in equilibration buffer (0.1M tris-HC1, pH 6.8, 6M urea, 
30% glycerol, 1% SDS) with 1% DTT followed by a 10min. incubation in 
equilibration  buffer  with 4.5% iodoacetamide and 0.1% bromophenol  blue. 
Equilibrated strips were laid across a 12% SDS-PAGE gel, sealed in with 0.5% 
agarose in stacking gel buffer (49) and run as 1D gels. Gels were either stained using a 
Novex Silver Express silver staining kit or transferred to nitrocellulose for western 
blot analysis. 
3.3.9 Western blotting 
SDS-PAGE gels were transferred to nitrocellulose using the Bio-Rad Mini-Protean II 
transfer cell in transfer buffer (25mM tris base, 192mM glycine, pH 8.03, .01% SDS, 
20% methanol) at room temperature at 50V for 45 min. or 90 min. for 1D (0.75mm) or 
2D (1.5mm) gels, respectively. Blots were blocked with 5% BSA in TBS-T (0.1M 
tris -HCI, pH 7.2, 0.2M NaC1, 0.1% tween-20) at 10°C overnight. Blots were then 
incubated with 1:1000 polyclonal Sheep anti-CORT 1° antibody for 1 hour in 5% 
BSA, TBS-T at room temperature followed by 3 X 15 min. washes with TBS-T. Blots 
were then incubated with monoclonal Donkey anti-Sheep IgG 2° antibody in TBS-T 
for 1 hour at room temperature followed by 7 X 10 min. washes in TBS-T. Blots were 48 
developed using ECL Super Signal Substrate and visualized by autoflourograph 
detection using Fuji RX X-Ray film. 
3.3.10 Photoaffinity labeling studies 
Azido-CORT was synthesized as previously described (46). Membrane extract  was 
diluted 2.5-fold with buffer/0.2M NaC1 and samples were incubated with either 1011M 
CORT or vehicle (0.1% ethanol) for 1 hour at room temperature. Azido-CORT was 
then added to sample to a concentration of 21.1M (10X it's Ki) and incubated at room 
temperature for 2 hours. Samples were incubated on ice for 10min. then exposed to 
254nm UV irradiation using a Spectroline hand held UV lamp (Spectronics 
Corporation, Westbury, New York) for 5 min. with gentle shaking on ice. Samples 
were then loaded directly onto WGA-agarose resin and treated as described for 
western blotting and in results section text. 
3.4 Results 
All procedures discussed were repeated several times and shown to be reproducible. 
Chromatographs given in the figures come from individual experiments but are 
representative of results obtained across experiments. 
3.4.1 Ammonium sulfate fractionation 
To determine if the newt mGR could be enriched by ammonium sulfate fractionation, 
solubilized newt neuronal membrane proteins were fractionated by precipitation with 
increasing concentrations of ammonium sulfate. Pellets from each precipitation step 
were resuspended for quantification of total protein by absorbance at 280nm (A280) 
and quantification of receptor binding activity by [3H]CORT binding assays (Fig. 49 
3.1a). Receptor binding activity was recovered in the 80 to 100% saturated ammonium 
sulfate fractions whereas the majority of total protein precipitated at earlier points. 
Since the receptor precipitated toward the extreme end of total protein precipitation a 
second experiment was performed with expanded resolution in the receptor positive 
range (Fig. 3.1b). A single cut of 70% to 95% saturated ammonium sulfate was 
determined to give the optimal enrichment and yield of the receptor and was thus 
utilized for future experiments. 
3.4.2 Ion exchange chromatography 
A weak anion exchange resin, DEAE-Sepharose, and a strong cation exchange resin, 
CM-Sepharose, were evaluated to determine whether ion exchange chromatography 
can enrich the newt mGR. No [311]CORT binding activity was recovered in the flow-
through and wash fractions of the anion exchange resin, whereas 95% of binding 
activity was recovered in these fractions from the cation exchange resin (data not 
shown). This suggests that mGR is an anionic protein at physiological pH. However, 
recovery of receptor from the DEAE Sepharose resin was poor (<20%) and 
inconsistent from run to run. Furthermore, no enrichment of receptor over total protein 
was observed. Thus ion-exchange chromatography was not utilized further. 
3.4.3 Hydroxylapatite chromatography 
Hydroxylapatite resin was evaluated for potential use in a receptor enrichment 
strategy. Solubilized membrane proteins were loaded onto a hydroxylapatite column 
and then step eluted with low potassium phosphate followed by high potassium 
phosphate (Fig 3.2). Greater than 50% of total protein was always recovered at the low 
potassium phosphate elution step with the majority of receptor activity eluting at high 
salt concentration. At least 0.5M potassium phosphate was required for efficient 
(>50%) recovery of receptor activity. Although the interactions of proteins with 50 
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Figure 3.1. Ammonium sulfate fractionation of solubilized neuronal membrane 
proteins.  Proteins  were precipitated with increasing concentrations of ammonium 
sulfate followed by removal of precipitate by centrifugation and resuspension of 
pellets in buffer C. Total protein was quantified by absorbance at 280nm and receptor 
binding activity was quantified by [31-11corticosterone binding assays. Values are 
reported as percent total in reference to total protein or total specific binding activity 
in the pre-precipitate sample. A) Initial fractionation over a broad range of ammonium 
sulfate  concentrations. B) Expanded fractionation through ammonium sulfate 
concentrations positive for precipitation of membrane corticosterone receptor binding 
activity. 51 
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Figure 3.2. Hydroxylapatite chromatography. 0.4m1 membrane extract diluted with 
0.6m1 buffer A (1m1 total) was loaded onto a 0.5ml hydroxylapatite column 
equilibrated with buffer B/20mM potassium phosphate, pH 7.45. Proteins were step 
eluted with potassium phosphate as shown on the graph. Total protein was quantified 
by absorbance at 280nm and receptor binding activity with [3H]corticosterone binding 
assays. 52 
hydroxylapatite are not completely understood, they are predominately ionic. The 
observation that the receptor activity elutes at higher salt concentrations of the bulk 
protein at a high salt concentration suggests that the receptor is likely a highly charged 
protein. 
3.4.4 Lectin affinity chromatography 
Lectins bind carbohydrate moieties on glycoproteins and are thus useful in the 
purification of many membrane proteins. The lectin affinity resin, wheat germ 
agglutinin (WGA)-agarose was selected for evaluation in a partial purification scheme. 
Solubilized membrane proteins were loaded onto WGA-agarose resin and then eluted 
with n-acetylglucosamine (NAG) (Fig. 3.3). Because NAG has a significant negative 
effect on [3H]CORT binding assays the eluent had to be desalted over a G-50 
Sephadex column prior to assaying for receptor activity. Approximately 90% of total 
protein remained unbound to the WGA-agarose resin and was collected in the flow-
through and wash fractions, as compared to a loss of about 15% of the receptor 
activity in these fractions. About 40% of receptor activity was recovered in the eluent 
fractions with only about 4% of total protein. Due to the necessary G-50 desalting 
step, however, the recovery of receptor activity is probably underestimated. These data 
show WGA-agarose to be efficacious for enrichment of the newt mGR and also 
provide evidence that the receptor is a glycoprotein. 
3.4.5 CORT-Sepharose chromatography 
Corticosterone-Sepharose was evaluated for efficacy in a purification scheme. Specific 
binding of the receptor to the affinity resin was shown using binding activity depletion 
assays (Fig. 3.4). Solubilized membrane proteins were loaded onto either CORT-
Sepharose or blocked (blank) Sepharose. The flow-through fractions were checked for 
both total protein and receptor binding activity and compared to pre-resin controls. For 
both resins the recovery of total protein in the flow-through fractions was 53 
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Figure 3.3. WGA-agarose chromatography. 2m1 of solubilized membrane proteins 
in buffer B/0.2M NaC1 were loaded onto 1 ml of wheat germ agglutinin agarose resin 
and allowed to mix as a slurry overnight at 4°C in a sealed glass column in an end­
over-end manner. The column was then drained and washed with 10 volumes buffer 
B/0.2M NaCl. Proteins were eluted by resuspending the drained resin in 0.2M 
NAG/buffer B/0.2M NaCl. The resultant slurry was then incubated one hour prior to 
draining the eluent fraction from the resin. Total protein was quantified by absorbance 
at 280nm and receptor binding activity by [3H]corticosterone binding assays after 
desalting over a G-50 Sephadex column. 54 
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Figure 3.4. CORT-Sepharose affinity chromatography. 0.5m1 of CORT-Sepharose 
and 0.5m1 of blank (blocked) Sepharose were loaded with lml of solubilized 
membrane proteins in buffer B/0.5M NaC1 and allowed to mix overnight at 4°C in an 
end-over-end manner in sealed glass columns. Columns were drained and the unbound 
fraction assayed for total protein concentration by absorbance at 280nm and for 
receptor binding activity using [3EI]corticosterone binding assays. 55 
approximately 70%. The recovery of receptor activity in the flow-through fractions, 
however, was only about 10% from the CORT-Sepharose and near 70% (similar to 
total protein) from the blocked Sepharose. This shows specific binding of the receptor 
by the CORT-Sepharose affinity resin. 
Elution from the CORT-Sepharose resin was achieved by disruption of binding to the 
column by either competition with excess free CORT or stripping the column with a 
high salt/low pH shock. In control experiments, independent of exposure to Sepharose 
resin, receptor activity could not be recovered from either of these conditions. In the 
one case, excess free CORT was added to control membrane extract and in the second 
membrane  extract  was  adjusted  to  1M  NaC1,  pH  4.  Gel-filtration, 
microconcentration/dilution, or dialysis were used as methods to restore binding assay 
conditions; however, no [3H]CORT binding activity could be recovered. Therefore, it 
was impossible to estimate receptor protein in eluents from the CORT-Sepharose 
affinity resin because the elution process irreversibly destroyed receptor activity. 
3.4.6 Partial purification of mGR with sequential chromatographies 
The chromatographic methods that provided reasonable enrichment of the receptor 
were performed sequentially to achieve partial purification of the receptor protein. 
Because of the limited source of starting material, binding assays and A280 readings 
were limited to pooled flow-through and eluent fractions and the data are reported in 
tabular format (Table 3.1). The mGR was initially enriched by ammonium sulfate 
fractionation followed by sequential chromatographic purification over WGA-agarose, 
hydroxylapatite and CORT-Sepharose. Eluents from each step were assayed for total 
protein and receptor activity. Also, an aliquot of each eluent was analyzed by SDS­
PAGE (Fig. 3.5). Receptor enrichment could be estimated through the first three 
purification  steps,  culminating  in  approximately  50-fold  enrichment  in  the 
hydroxylapatite resin eluent. Calculations of enrichment from the final purification 
step are impossible because of the inability to perform radioligand binding assays on 57 
Table 3.1. Progress of receptor purification 
Fraction  specific activity  yield  fold 
(fmol/mg protein)  (% total)  enrichment 
1. membranes  76  100  1 
2. detergent extract  66  64  0.87 
3. ammonium sulfate pcpt.  210  31  2.8 
4. WGA-agarose eluent  370*  13*  4.9* 
5. hydroxylapatite eluent  3,760  10  50 
*receptor in WGA fractions is underestimated due to inhibition of [ H]corticosterone 
binding by NAG. 58 
the CORT-Sepharose column eluent fraction. However, the purification of a protein to 
near homogeneity is observed in corticosterone-Sepharose affinity column eluent 
visualized on a silver stained SDS-PAGE gel (Fig 3.5). This protein has an observed 
molecular weight of approximately 63 kDa. 
3.4.7 Protein differential display with CORT-Sepharose 
Because of the inability to recover binding activity in the CORT-Sepharose column 
eluent an alternate strategy was developed to visualize receptor protein on a SDS­
PAGE gel. For this two CORT-Sepharose affinity columns were run in parallel. The 
first column (column 1) was loaded with solubilized membrane proteins, containing 
the receptor that could bind to the affinity resin. The second column (column 2) was 
loaded with membrane proteins pre-incubated with CORT. In this second case, the 
receptor's binding site would be occupied and presumably unavailable for specific 
interaction with the affinity resin so the majority of receptor was removed in the wash 
(Fig 3.6b). Thus mGR protein should be present in the eluent from column 1 and 
absent in the eluent from column 2. SDS-PAGE analysis of these eluents is shown in 
Fig. 3.6a. A protein with an apparent molecular weight of 63 kDa is seen in the eluent 
from column 1 and absent from that of column 2. These data are consistent with the 
identification of a 63 kDa protein by the purification scheme. 
3.4.8 Photoaffinity labeling of mGR 
Previous work described the synthesis of a novel azido-CORT ligand and found it to 
have nanomolar affinity for the newt mGR (46). This ligand was used in a 
photolabeling strategy as an independent method to identify mGR on a SDS-PAGE 
gel. Our photolabeling strategy was unique because we did not use a radiolabeled 
ligand to detect photolabeled proteins. Instead a western blot methodology was used 
with an antibody against corticosterone to visualize proteins that had been labeled with 
azido-CORT. As shown in Fig. 3.7, azido-CORT binds the membrane corticosterone 59 
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Figure 3.6. mGR differential display. A) 2.5mls of solubilized membrane proteins in 
buffer B/0.5M NaCI were equilibrated for 1 hour at room temperature with either 
10µM corticosterone or vehicle (0.1% ethanol) then loaded onto identical lml 
corticosterone-Sepharose affinity resins and allowed to mix overnight at 4°C in and 
end-over-end manner. Columns were drained and washed with 5 column volumes 
buffer B/0.5M NaCl. Columns were then eluted with 0.2M sodium acetate, pH 4.0, 
1M NaCl. Eluent was desalted by washing in a 5K molecular weight cut-off 
centrifugal concentrator and finally concentrated to a volume of 10111 for dilution into 
SDS-PAGE loading buffer for resolution of proteins by 12% gels. Proteins were 
visualized by silver staining. B) Columns were loaded as in A except proteins were 
pre-liganded with either 50nM [3H]CORT (instead of 1011M cold CORT) or vehicle 
prior to loading columns. [3H]CORT was then added to the flow-through fraction of 
the unliganded sample so that total CPM's in both the pre-liganded and un-liganded 
flow through fractions were equal prior to determing [311]CORT binding activity in 
these fractions. [3H]CORT binding activity is plotted normalized to total protein 
concentration and relative to sample loaded on to columns. 60 
receptor with a Ki of approximately 200nM (Fig. 3.7a) and cross-links the receptor 
with greater than 50% efficiency (Fig. 3.7b). Running a dilution series of CORT-3­
CMO-BSA through a western blot procedure using an anti-CORT primary antibody 
(Fig 3.7c) shows successful detection of labeled proteins with femtomolar sensitivity. 
The covalent linkage of CORT to BSA is identical to the linkage of CORT to the 
azido moiety in the azido-CORT molecule. Thus the CORT epitopes available on the 
CORT-3-CMO-BSA should be identical to the CORT epitopes available on the azido-
CORT. This western blot procedure proved sensitive enough to detect approximately 
50 fmol of CORT. BSA alone was used as a negative control to verify that signal was 
not obtained from any BSA epitopes. 
From these data, a calculation indicates that 1 mg of total starting protein is required to 
successfully detect mGR by this methodology. This calculation is derived from a 
receptor specific activity of 100 fmol/mg protein in P2 membrane preparations (26), a 
photolabel cross-linking efficiency of 50%, and a detection limit of 50 fmol mGR. 
High non-specific labeling in initial experiments, however, suggested a preliminary 
purification step was required in order to visualize any specifically labeled proteins. 
WGA-agarose was chosen for this because it showed the highest level of enrichment 
of receptor protein compared to the other purification methods and since WGA­
agarose binds  carbohydrate moieties of glycoproteins,  it  was assumed that 
photolabeling of the receptor's binding site would not interfere with this purification 
technique. Azido-CORT labeled mGR was thus  visualized by western blot 
methodology following enrichment by WGA-agarose chromatography (Fig. 3.8a). 
This showed two bands of approximately 63 and 58 kDa in which label was 
specifically displaced by excess CORT. To further evaluate the proteins identified in 
the photolabeling strategy, the labeling experiments were repeated followed by 2D gel 
electrophoresis (Fig. 3.8b). This experiment identified two spots with apparent 
molecular weights of 63 and 58 kDa as seen on the 1D gel. The 63 kDa spot had an 
approximate pI of 5.0 and a multi-spot pattern characteristic of a glycoprotein. This 
observation is consistent with expectations of mGR, that was predicted by the 61 
Figure 3.7. Preliminary studies of azido-CORT photolabeling strategy. A) Azido-
CORT was synthesized as previously described (46) then used in an equilibrium 
competition assay. P2 membrane preparations were used with approximately 1001.tg 
total protein per assay tube. All tubes received [3H]corticosterone to a final 
concentration of 0.8 nM and azido-CORT to concentrations indicated on graph. 
Binding assays were done in 300111 25mM HEPES, pH 7.45, 10 mM MgC12, 100p,M 
PMSF and allowed to incubate 4-6 hours at room temperature in total darkness. 
Assays were terminated by rapid filtration over GF/C glass fiber filters equilibrated in 
cold assay buffer. A K, of 163nM was calculated from this batch of azido-CORT in 
reasonable agreement with previous batches. B) P2 membrane preparations of 
approximately lmg protein each were incubated with either azido-CORT or vehicle (4 
preparations for each condition). Membranes were chilled by shaking in an ice bath 
for 10 minutes then irradiated for the time shown on graph. Membranes were pelleted 
by centrifugation at 40,000 x g and washed 3 times in 25mM HEPES, pH 7.45 by 
resuspension and re-centrifugation. Final pellets were subjected to [3H]corticosterone 
binding assays as above. C) CORT-BSA was subjected to western blot analysis as 
described in methods. Lanes were loaded with amounts given in the figure expressed 
as mols CORT. Detection of CORT was between 14 and 140 fmol. BSA was run as a 
control to ensure the antibody was not detecting epitopes on BSA itself. 10-fold more 
BSA than the highest level of BSA-CORT showed no signal. 62 
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Figure 3.8. Detection of mGR by photoaffinity labeling. A) 1 ml of membrane 
extract was diluted to 2.5 ml with buffer A and incubated with either 101.1.M CORT or 
vehicle (0.1% ethanol) for 1 hour at room temperature. Proteins were then labeled with 
211M azido-CORT (10X it's IQ) for 2 hours at room temperature. Reactions were 
chilled 10 min. in an ice bath prior to UV irradiation at 254nm for 5 minutes while 
shaking on ice. Reactions were loaded directly on to 1 ml WGA-agarose resin and 
receptor enriched as described in the WGA-agarose chromatography section. Eluents 
were desalted by centrifugal concentrators, diluting eluent 2X 20-fold with 25 mM 
HEPES, pH 7.45 prior to precipitation of total proteins with 80% acetone at 20°C 
overnight. Proteins were pelleted at 2,000 x g and resuspended in SDS-PAGE loading 
buffer for electrophoresis and western blot analysis as described in methods. B) 
Samples were prepared as in A except acetone pellets were resuspended in IPG 
rehydration buffer and run out on 2D gels as described in methods. 64 
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chromatographic data to be an acidic glycoprotein with an apparent molecular weight 
of approximately 63 kDa. 
3.5 Discussion 
The current study describes methods for the partial purification of a membrane 
corticosterone  receptor from newt neuronal membranes. Ammonium sulfate 
fractionation followed by WGA-agarose and hydroxylapatite chromatographies 
provided significant enrichment of the newt mGR. Purification of a 63 kDa protein to 
near homogeneity was completed with the use of a CORT-Sepharose affinity resin. 
Furthermore, photoaffinity labeling followed by 1D or 2D SDS-PAGE gels identified 
a protein with an molecular weight of 63 kDa, consistent with the purification 
experiments. These studies have successfully identified steps in the purification of the 
newt neuronal mGR that can be used in future experiments for a large scale 
purification of this protein to gain primary amino acid sequence information. 
In addition to identifying purification techniques, these studies provided insights into 
the biochemical characteristics of the newt mGR. Ion exchange and hydroxylapatite 
chromatographies suggest the mGR is an anionic protein with a high charge. WGA­
agarose chromatography provided evidence that the mGR is a glycoprotein. Three 
independent strategies  (purification by sequential chromatographies, differential 
display using CORT-Sepharose affinity chromatography, and photolabeling with 
western blot detection) all identified a protein with an apparent molecular weight of 
63kDa. Two-dimensional SDS-PAGE gels following photolabeling revealed that this 
protein has a pI of approximately 5.0, confirming that it is anionic. Taken together, 
these data suggest that the newt neuronal mGR is an acidic glycoprotein with an 
apparent molecular weight of 63 kDa. 
Recent evidence indicates that, in some cases, steroid membrane receptors might 
actually be related to classical intracellular steroid receptors that are associated with 66 
the plasma membrane. Membrane proteins in lymphocytes have been labeled with 
antibodies against the intracellular glucocorticoid receptor (iGR) (45,50-52). Anti-
estrogen receptor (ER) antibodies have also been used to detect immunoreactive 
proteins in rat pituitary tumor cells (53,54) and in the plasma membranes of CHO cells 
transfected with ER cDNA (53). The current study provides evidence that the newt 
neuronal mGR and iGR are distinct proteins. The iGR is known to migrate on SDS­
PAGE at around 96 kDa and is not known or expected to be glycosylated whereas the 
mGR appears to be a glycoprotein with an apparent molecular weight of 63 kDa. 
These biochemical properties taken together with the pharmacological, behavioral and 
neurophysiological properties of mGR, discussed in the introduction, strongly suggest 
that the newt mGR and iGR are indeed distinct receptors. However, the structure of 
mGR and its relationship, if any, to iGR can only be elucidated by complete molecular 
characterization. 
Previous reports on the purification of other steroid membrane receptors have 
interesting parallels with the current study. The purification of a cortisol binding 
protein from rat hepatic membranes revealed two proteins of 52 and 57 kDa when 
analyzed by SDS-PAGE (36). High resolution size-exclusion chromatography 
suggested that these two proteins may heterodimerize to form the functional receptor. 
Using an azido-progesterone photolabel, two proteins were identified in porcine liver 
microsomes with apparent molecular weights of 60-65 kDa and 90-100 kDa (43). 
Native gel analysis suggests that these proteins may also be components of larger 
functional receptors. The current study identified two proteins of approximately 58 
and 63 kDa using an azido-CORT photolabel. It is intriguing to speculate that the 
failure of expression cloning strategies to identify steroid membrane receptors may be 
due to the requirement for a heterodimer to achieve high affinity binding activity. 
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Chapter 4 
Evidence that a Membrane Glucocorticoid Receptor in Amphibian Brain 
is Pharmacologically Related to the Kappa Opioid Receptor 
Simon J. Evans, Brian T. Searcy, and Frank L. Moore 71 
4.1 Abstract 
A membrane glucocorticoid receptor (mGR) has previously been described in the 
roughskin newt (Taricha granulosa). This receptor has characteristics of a G-protein 
coupled receptor because [3H]corticosterone (CORT) binding is inhibited by guanyl 
nucleotides and enhanced by Mg2+. The present study screened various G-protein 
coupled receptor ligands for binding activity at mGR. Of the ligands tested, only those 
that are known to bind the kappa opioid receptor (KOR) showed any binding activity 
at mGR. Using equilibrium competition studies, it was shown that dynorphin (1-13 
amide), U-50,488, naloxone, bremazocine, and ethylketocyclazocine (EKC) displaced 
[3H]CORT from the mGR binding site with nanomolar to low micromolar affinity. 
KOR ligands that had no activity at mGR included U-69,593, etorphine, nor-BNI, and 
diprenorphine. No mu-, delta-, or orphanin-specific opioids had any effect in 
[3H]CORT competition assays. Kinetic analysis of [3H]CORT off-rates in the presence 
of the opioid competitor U-50,488, or CORT revealed no differences in k_i values, best 
supporting a single site competition model. However, a maximum of only 70% 
displacement was seen in the presence of U-50,488, naloxone, bremazocine, or EKC 
and a maximum of only 25% displacement was seen by dynorphin 1-13amide, 
suggesting that some [3H]CORT binding sites are opioid insensitive. These data 
suggest that the newt neuronal mGR may be related to the kappa-opioid receptor but 
that these two receptors are most likely distinct. 
4.2 Introduction 
Steroid hormones are known to induce intracellular receptors to modulate the 
transcriptional activity of genes containing cis-acting response elements in their 
promoter regions. This "genomic" model of steroid hormone action is undisputed but 
cannot fully explain all observations of responses to steroids. The hypothesis that 
steroids also have "nongenomic" actions has gained support over the past few decades. 
Several studies show rapid effects of steroid hormones, too fast to be accounted for by 
the genomic model of transcriptional regulation, or show effects of steroid hormones 72 
in isolated membrane preparations that lack a cell nucleus. Several recent reviews are 
devoted to these observations of steroid hormone effects (1-7). 
In a few cases, known membrane proteins have been shown to be targets for specific 
steroid action. Progesterone and glucocorticoid metabolites have been shown to 
modulate GABAA receptor activity in neuronal membranes (8,9), providing a possible 
explanation for the rapid analgesic effects of progesterone. Estrogen (17(3-estradiol) 
has been reported to bind to and activate the kinase activity of the oncogene ErbB2 (an 
EGF receptor-like protein) in vitro (10). This protein is believed to play a role in 
breast cancer (11,12). Progesterone has been shown to bind the oxytocin receptor and 
inhibit oxytocin binding and activity in vivo and in vitro (13). And a putative 
membrane progesterone receptor that has high affinity for sigma ligands (14) has been 
cloned from porcine vascular smooth muscle (15). 
In most cases membrane targets of steroid hormones remain unknown. Such is the 
case for a membrane glucocorticoid receptor (mGR) in neuronal membranes of an 
amphibian, the roughskin newt (Taricha granulosa). The newt mGR has been 
localized to membrane sub-cellular fractions and shown to bind corticosterone 
(CORT) with specificity and high affinity (16). The receptor has characteristics of a 
G-protein coupled receptor in that [31-]CORT binding is modulated by the presence of 
either guanyl nucleotides or Mg2+. The mGR has been solubilized from newt neuronal 
membranes ((17), Chapter 2) and shown to be an acidic glycoprotein with an apparent 
molecular weight of 63 kDa (Chapter, 3). 
The newt neuronal mGR is thought to play a role in the control of sex behavior. CORT 
has been shown to rapidly inhibit sex behavior in male newts (18) and this may be 
mediated by mGR because the affinities of various steroids for mGR correlate with 
their potencies in sex behavior assays (16). Other studies in newts have shown that 
gonadotropin-releasing hormone (GnRH) (19,20), vasotocin (AVT) (21,22), and 
kappa-opioids (23) also play roles in the control of sex behavior. Both the GnRH and 
AVT systems have also been shown to interact with CORT in newts. Stress or 73 
exogenous CORT has been shown to  increase GnRH immunoreactivity  in 
hypothalamic neurons, most likely by inhibiting GnRH release (19). And vasotocin­
induced neuronal activity in newt brain is susceptible to rapid modulation by CORT 
(24). 
The current study hypothesized that mGR might be a known receptor and that CORT 
induces rapid effects by modulating this receptor, either directly or indirectly in 
response to another hormone. This was based on two primary premises. First, a few 
known receptors have been shown to be targets for modulation by steroid hormones, 
as discussed above, and this might be a general theme for rapid steroid action. Second, 
CORT might exert its effects on sex behavior by direct interaction with a known 
receptor involved in the control of this behavior. GnRH, AVT, and kappa opioids, 
which are involved in the control of sex behavior, all signal through G-protein coupled 
receptors, which mGR is also suspected to be. To evaluate if mGR might be a known 
G-protein coupled receptor, the current study screened these and other known G-
protein coupled receptor ligands for activity as competitors in [3H]CORT binding 
assays. 
4.3 Materials and Methods 
All buffers, salts, and drugs were from Sigma Chemical Co. (St. Louis, MO) except 
diprenorphine, bremazocine, U-50,488, and U-69,593 were from RBI (Natick, MA); 
dynorphin  (1-13  amide) was from  Peninsula  Laboratories  (Belmont,  CA); 
ethylketocyclazocine (EKC) was originally from Sterling Winthrop and was obtained 
as a gift from Dr. Thomas Murray (University of Georgia).  [3H]corticosterone (79 
Ci/mmol) was from Amersham (Arlington Heights, IL). GF/C membranes were from 
Brandel (Gaithersburg, MD). Newts (Taricha granulosa) were collected from local 
ponds and maintained in tanks with continuously flowing de-chlorinated water. 
Animals were treated in compliance with IAUAC standards and guidelines as 
approved by the Animal Use and Care Committee at Oregon State University. 74 
4.3.1 Preparation of neuronal membranes 
P2 membrane pellets were prepared by the method of Whittaker (25) with some 
modification. Brains were removed and resuspended in 0.3m1 of homogenization 
buffer (0.32M Sucrose, 5mM HEPES, pH 7.45, 10011M PMSF) per mg brain tissue 
(wet weight) and homogenized with a teflon-on-glass tissue homogenizer. The 
homogenate was pelleted at 1,000 x g for 10 minutes at 4°C and the resultant 
supernatant (Si) was transferred to a clean centrifuge tube. The pellet (P1) was 
resuspended in homogenization buffer to the original concentration and centrifuged 
again as above. The pellet was discarded and the supernatant was pooled with Si and 
centrifuged at 30,000 x g for 40 minutes at 4°C. The pellet (P2) was quick frozen at 
80 °C, then thawed on ice and resuspended in 0.18 ml/mg (original tissue weight) of 
25mM HEPES, 10mM EDTA, pH 7.45, 100tiM PMSF. The suspension of P2 was 
incubated at 4°C for 2 hours to allow the dissociation of any endogenous ligand and 
centrifuged at 40,000 x g. The resultant pellet was washed once with 25mM HEPES, 
pH 7.45 prior to freezing at 80°C. Pellets were either stored for up to several weeks at 
80°C or thawed on ice and used immediately. No loss of binding activity was 
observed in stored pellets. 
4.3.2 Radioligand binding assays 
[3H }CORT binding assays were performed as previously described (16). Briefly, 
membrane proteins were resuspended in 25mM HEPES, pH 7.45, 10mM MgC12 at a 
concentration of 100[1g / 300t1 and 300  111 were used in each assay tube. 
[31Thorticosterone was present at a concentration of 0.5nM (near it's KD (16)) and 
non-specific binding was defined in the presence of 101.1M corticosterone. Competitors 
were present at concentrations indicated in the results section. Binding was allowed to 
reach equilibrium at 30°C over 4-6 hours and binding was terminated by rapid 75 
filtration over GF/C glass fiber filters equilibrated in cold assay buffer. CPMs were 
determined using a Beckman LS 6500 scintillation counter. All radioligand binding 
data were analyzed with Graphpad Prism software. 
4.4 Results 
4.4.1 Screening of G-protein coupled receptor ligands 
To evaluate if the mGR might be a known receptor, competition binding studies were 
performed with select ligands for various G-protein coupled receptors (Fig. 4.1). This 
experiment was intended to screen for ligands that might have activity at mGR, and all 
points were only performed as singles; thus, the estimates are likely to contain large 
errors. The only ligands that showed activity in these initial competition experiments 
were three ligands that are known to bind the kappa-opioid receptor (KOR). Naloxone 
and U-50,488 showed greater than 50% displacement of [3H]CORT- specific binding, 
and dynorphin 1-13 amide showed greater than 25% displacement. No other ligands 
tested provided any reasonable displacement of [3H]CORT binding activity. 
4.4.2 Equilibrium competition analysis with kappa-opioid receptor ligands 
Because of the activity of KOR ligands in the competition screening assay, these and 
other KOR ligands were tested with expanded equilibrium competition assays (Fig. 
4.2). These experiments reproducibly showed five opioids to have activity in 
[3H]CORT competition binding assays. U-50,488, naloxone, bremazocine, and EKC 
had a maximal effect of approximately 70% displacement of specific [3H]CORT 
binding with K1 values of approximately 250nM,  9.6p.M and 161AM 
respectively. These data conformed to a single site-competition model with r2 = 0.98, 76 
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Figure 4.1. Multiple ligand screen. [3H]CORT competition binding  assays were 
performed as described in the methods section. All competitors were added to assays 
to a final concentration of 10uM. Values are reported as percent of control of 
[3WORT specific  binding  as  determined  in  the  presence of 10p.14  cold 
corticosterone. 77 
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Figure 4.2. Equilibrium competition analysis with kappa opioid receptor ligands. 
Binding assays were performed as described in the methods section. Competitors were 
present at the concentrations indicated on the graph. A) Competitors showing a 
maximum of 70% displacement of [3H]CORT binding. B) Dynorphin 1-13 amide 
competition curve showing a maximum of 25% displacement of [3H]CORT binding. 
Data were analyzed with Graphpad Prism software using a single site competition 
model. 78 
0.93, 0.96 and 0.87, for U-50,488, naloxone, bremazocine and EKC, respectively. 
Dynorphin 1-13amide showed high affinity for the [3H]CORT binding site with a sub­
nanomolar Ki. However, this ligand only displaced a maximum of 25% specific 
[3H]CORT binding. Other opioids tested with known activity at KOR including, 
diprenorphine, U-69,593, nor-BNI, and etorphine showed no activity in [3H]CORT 
competition binding assays. These data are summarized in Table 4.1. 
4.4.3 Kinetic analysis of dissociation rates 
4.4.3 Kinetic analysis of [3H]CORT dissociation rates 
Kinetic experiments were performed to  evaluate the possibility of allosteric 
interactions between the opioid and CORT binding sites (Fig. 4.3). These experiments 
were only performed with U-50,488 because this was the only opioid ligand that 
showed both nanomolar affinity for mGR and activity at a high % of [3H]CORT 
binding sites. U-50,488, and CORT were found to displace [3H]CORT with no 
difference in dissociation rates with LI values of 8.6 x 10-3 + 0.0014 and 9.5 x 10-3 + 
0.0017, respectively. When both competitors were present together, k..1 was unchanged 
with a value of 9.0 x 10-3 + 0.0009. Both dissociation curves fit a one-phase 
exponential decay model with r2 equal to 0.95 and 0.94 for CORT and U-50,488 
curves, respectively. With both competitors present r2 was equal to 0.98. 
4.5 Discussion 
The present study shows that some KOR ligands show activity at the newt neuronal 
mGR. These include the kappa-specific agonists U-50,488, bremazocine, and 
dynorphin 1-13 amide, the non-specific opioid agonist EKC, and the non-specific 
opioid antagonist naloxone. The competition by these ligands for the [3H]CORT 
binding site was consistent with a single-site competition model and no differences in 
off-rates were observed in the presence of either the opioid competitor, U-50,488 or 
CORT, providing further support for this model. However, 100% displacement of the 79 
Table 4.1. Summary of equilibrium competition binding with opioid competitors. 
Opioids positive for activity in [3H]CORT competition binding assays are listed with 
calculated Ki values and extrapolated bottom values. Data were analyzed with 
Graphpad Prism software using a single-site competition model. 
competitor 
U-50,488 
Naloxone 
Bremazocine 
EKC 
dynorphin (1-13 amide) 
U-69,593 
diprenorphine 
nor-BNI 
etorphine 
Ki (displacing [3H]CORT) 
250 nM 
2.8 p.M 
9.6 pM 
16 pM 
<1 nM 
-
-
-
max. displacement 
70% 
70% 
70% 
70% 
25% 
0% 
0% 
0% 
0% 80 
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Figure 4.3. Kinetic analysis of dissociation rates. Binding assays were set up as 
described in the methods section and allowed to equilibrate for 6 hours prior to adding 
competitors. Both U-50,488 and CORT competitors were added to achieve final 
concentrations of 10gM. Dissociation time points were initiated in an inverse order 
and assays were terminated simultaneously by rapid filtration as described in methods. 
Data were analyzed with Graphpad Prism software using a one phase exponential 
decay to determine k..1 values. Data are normalized to maximum displacement of 
[3I-]CORT by either U-50,488 or CORT. 81 
[3H]CORT was not achieved in the presence of the opioid competitors, suggesting that 
a sub-population of the [3H]CORT binding sites are opioid insensitive. 
The affinities of the opioid ligands for the newt mGR and their rank order potencies 
are inconsistent with any known opioid receptors (OR's). A recent study of PCR 
amplified OR gene fragments across diverse vertebrate phyla show that the four 
receptor subtypes (mu-, delta-, kappa-, and orphanin-OR) are present in shark, bass, 
frog, chicken and various mammalian species (26), suggesting that newts are also 
likely to have these receptors. However, preliminary experiments using [3H]U- 69,593 
to detect a KOR in newt neuronal membrane preparations were unable to achieve 
saturable binding at a concentration of 20 times its KD in mammalian membranes 
(unpublished data). This suggests that the newt KOR may be pharmacologically 
different than its mammalian counterpart. Thus conclusions about the current data, 
based on the pharmacological profile of KOR from mammalian studies, should be 
cautious. Nonetheless, the specificity of mGR for kappa-opioid ligands suggests this 
receptor may be related to KOR. However, the modest affinities of the active kappa-
opioid ligands and the lack of affinity of others suggest that KOR and mGR are most 
likely distinct. 
Previous studies have observed direct actions of steroids at opioid receptors, 
suggesting a physiological relationship between steroids and opioids. The anti-
glucocorticoid/progesterone, RU486, displaces [3H]dihydropmorphine from mu-opioid 
receptors (MOR) in rat and mouse neuronal membranes (27). Estrogens have been 
shown to inhibit binding of the opioid peptides [3H]DAGO and [3H]DADL in rat brain 
membrane preparations (28). Progesterone inhibits binding of sigma receptor ligands 
in mammalian brain  (29),  and  conversely,  sigma receptor  ligands  inhibit 
[3H]progesterone binding to porcine liver membrane sites (14). The current study adds 
observations to this emerging theme with the inhibition of [3H]CORT binding to a 
membrane receptor by kappa-opioid ligands. 82 
Several studies have shown an interaction between the opioid  system and the 
hypothalamic-pituitary-adrenal (HPA) axis, which regulates CORT release from the 
adrenal glands using a pituitary peptide, adrenocorticotropin (ACTH). Corticotropin­
releasing factor (CRF) and arginine vasotocin (AVT) are both potent stimulators of 
ACTH  release from pituitary (30-32), and the endogenous KOR agonist dynorphin, 
has been co-localized with both CRF, in hypothalamic neurons (33), and with AVT,  in 
pituitary cells (34). This suggests that co-activation of both the HPA  and the kappa-
opioid system may occur in some cases. Possible co-activation of the HPA  and opioid 
system is also evident by the proopiomelanocortinin (POMC) peptide, which contains 
both the opioid peptide f3-endorphin, and ACTH. Exogenous manipulation of the 
opioid system can also influence the activity of the HPA axis as measured by increases 
in glucocorticoid serum levels (35-40) providing further evidence for "cross-talk" 
between these two systems. Furthermore, in newts, CRF and the opioid system have 
been shown to converge on the regulation of spontaneous locomoter activity (41), 
suggesting that an interaction between the HPA  and opioid system is also relevant in 
this amphibian model. 
Previous studies in newts have shown that the high affinity KOR ligand bremazocine 
inhibits sex behavior (23) and locomoter activity (42). These behavioral effects are 
reversed by naloxone and are not mimicked by mu- and delta- ligands, suggesting a 
specific involvement of kappa opioids in the regulation of these behaviors. CORT also 
rapidly inhibits sex behavior (18) and locomoter activity (43) in newts and the current 
study shows that KOR ligands, including bremazocine and naloxone, have activity at 
the newt neuronal mGR. These studies suggest that there may be a physiological 
relationship between CORT and endogenous kappa opioid ligands that might be 
mediated by mGR. Future studies aimed at the molecular characterization of mGR 
could lead to a more complete understanding of the relationship between these two 
complex neuroendocrine systems. 
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5.1 Abstract 
A membrane glucocorticoid receptor (mGR) has been described in the brain of the 
roughskin newt (Taricha granulosa). Pharmacological and behavioral studies suggest 
that this receptor is a member of the G-protein coupled receptor family and is involved 
in the control of sex behavior in male newts. The current study was aimed at 
molecular identification of mGR using a novel protein differential display strategy. A 
candidate receptor protein was identified using immobilized ligand affinity resins 
followed by 2D gel electrophoresis. Partial amino acid sequencing of this protein 
identified it as neuronal axonal protein 22 (NAP-22), a peripheral membrane protein 
thought to be involved in membrane dynamics and control of neurotransmitter release 
from axon terminals. This protein is known to be a protein kinase C (PKC) substrate 
and a calmodulin binding protein. Cloning of NAP-22 from a newt brain cDNA 
library and expression in a mammalian cells were successfully achieved. However, 
expression of the cloned NAP-22 protein did not reconstitute [3H]corticosterone 
(CORT) binding activity in vitro, suggesting this protein is not the membrane CORT 
binding site. Protein-protein interaction studies using a hexahistidine tagged NAP-22 
protein and the native mGR suggest that NAP-22 may interact with mGR, providing a 
plausible explanation for its identification in our protein differential display strategy. 
5.2 Introduction 
The most prominent model of steroid hormone action involves the activation of 
intracellular receptors by steroid hormones that effect cellular physiology through 
direct transcriptional regulation of target genes. This "genomic model" is well 
characterized and can explain many roles of steroid hormones. Several studies over the 
past few decades have suggested that steroids also exert some of their actions through 
"nongenomic processes" (for review see Wehling, 1997 (1), Moore and Evans, 1999 
0). Some of these nongenomic actions can effect classic signal transduction cascades 
on a time-scale too fast to be accounted for by the genomic model, suggesting the 
involvement of membrane receptors. For example estrogens can trigger rapid increases 88 
in cAMP concentration in isolated endometrial cells (2). Rapid increases in inositol 
triphosphate (IP3) and diacylglycerol (DAG) concentrations have been shown in 
various cell types following exposure to androgens (3), mineralocorticoids (3-5), and 
vitamin D3 (6). Rapid modulation of intracellular calcium concentrations are induced 
by progestins (7), corticosteroids (8), and estrogens (2). 
In a few cases, known membrane proteins have been identified as targets for steroid 
hormone action. Specific progesterone metabolites have been shown to have activity 
at the neural GABAA receptor (9) and progesterone can bind to and modulate the 
activity of the oxytocin receptor in vitro (10). Estradiol has been shown to bind to and 
activate the kinase activity of ErbB2 (11), an EGF receptor-like protein involved in 
breast cancer (12,13). In most cases, however, the molecular identity of membrane 
targets for steroids remain unknown. 
Glucocorticoids have rapid effects on sex behavior (14) and neuronal activity (15,16) 
in the roughskin newt (Taricha granulosa). The rapidity of these effects cannot be 
adequately explained by the genomic model. A membrane glucocorticoid receptor 
(mGR) has been described in this animal that is involved in the rapid control of sex 
behavior (17) and may also mediate the rapid neurophysiological responses to CORT. 
This receptor has been localized to membrane fractions (17) and has characteristics of 
a G-protein coupled receptor in that [3H]CORT binding is inhibited by guanyl 
nucleotides and enhanced by Mg2+. (18). The newt neuronal mGR has previously been 
solubilized from plasma membrane preparations (19) and shown to be an acidic 
glycoprotein with an apparent molecular weight of 63 kDa (Chapter 3). 
Molecular identification of the newt neuronal mGR would contribute to our 
understanding of how this steroid controls brain functions and behavior. Differential 
display strategies have gained popularity over recent years as powerful tools in the 
identification of both mRNA species and proteins that are involved in a variety of 
cellular processes. The current strategy utilized a differential display technique using 89 
immobilized steroid affinity chromatography resins and 2D gel electrophoresis to 
attempt to identify mGR from solubilized newt neuronal membrane preparations. 
5.3 Materials and Methods 
All buffers, solvents, and salts were purchased from Sigma Chemical Co. (St. Louis, 
MO). EAH-Sepharose 4B, ampholytes, and IPG strips were from Pharmacia 
(Piscataway, NJ). Steroid ligands were from Steraloids, Inc. (Wilton, NH). [3H]CORT 
(79 Ci/mmol) and was from Amersham (Piscataway, NJ). [3H]myristic acid (1mCi/m1) 
was from New England Nuclear (Boston, MA). Custom PCR primers and DMRIE-C 
transfection reagent were purchased from Gibco/BRL (Gaithersburg, MD). Taq DNA 
polymerase and deoxynucleotides (dNTP's) were from Promega (St. Louis, MO). The 
newt brain cDNA library was a gift from Ken Soderstrom (University of Florida). The 
pTM1 expression vector, originally described by Fuerst (20), was a gift from Dr. 
Dennis Hruby (Oregon State University). Ni-Agarose was from Qiagen (Valencia, 
CA). India-His Probe and enhanced chemiluminescent reagents were from Pierce 
Chemical Co. (Rockford, IL). 
5.3.1 Preparation of P2 membrane pellets and solubilization of membrane proteins 
Membrane pellets were prepared and membrane proteins solubilized as previously 
described ((19), Chapter 2, Chapter 3). 
5.3.2 Synthesis of affinity resins 
Affinity resins were synthesized by the condensation of the carboxyl groups of CORT-
or ALDO- 3- carboxymethyloxime  (- 3 -CMO) with the amino groups of EAH-
Sepharose 4B (Pharmacia). Sepharose resin was prepared by washing with 80 volumes 90 
0.5M NaC1 followed by 10 volumes ddH2O using a sintered glass filter. Washed resin 
was then mixed in a (1:1) slurry with either CORT -3 -CMO or ALDO -3 -CMO in 30% 
dioxane. One tenth volume of 1M aqueous  1-ethyl -3-(3-dimethylaminopropyl) 
carbodiimide (EDC) was added to the slurry to catalyze the reaction which was then 
incubated on a slow shaker overnight at 4°C. The affinity resin was washed with 10 
volumes 30% dioxane to remove any unreacted CORT- or ALDO -3 -CMO followed 
by alternating washes with 0.5M NaC1, pH 9.0 and 0.5M NaC1, pH 4.0. Finally, the 
resin was washed with 10 volumes ddH2O prior to loading into glass columns. 
5.3.3 Radioligand binding assays 
[3H]corticosterone binding assays were performed as previously described ((19), 
Chapter 2, Chapter 3). 
5.3.4 2D polvacrylamide gel electrophoresis 
Samples were concentrated to <501.11 and brought to 400111 with IPG rehydration buffer 
(8M urea, 0.3% DTT, 1% CHAPS, 1% triton X-100, 2% 3-10 ampholytes) and used to 
rehydrate 18cm IPG 3-10L strips overnight at room temperature. For preparative runs 
P2 membrane pellets (-5mg total protein) were resuspended directly in 40011.1 
rehydration buffer. Proteins were focused at 10°C over a voltage gradient ramping 
from 0 to 500V over 1 min., from 500 to 3500V over 1.5 hours then held at 3500V for 
12 hours using a Pharmacia LKB Multiphor II. Focused strips were then resolved in 
the 2'  dimension by 12.5% SDS-PAGE as described by Leammli (21). Gels were 
either stained with Novex Silver Express silver staining kit (Novex, San Diego, CA) 
for analytical gels or with coomassie blue for preparative gels. 91 
5.3.5 Peptide sequencing 
Peptide sequencing was performed at ZymoGenetics, Inc. (Seattle, WA). Appropriate 
2D gel spots were excised and proteins digested with trypsin as described by Hellman 
(22). Tryptic peptides were separated on a microbore (1mm i.d.) C18 HPLC column 
over a linear 5-95% acetonitrile gradient in 0.1% triflouroacetic acid (TFA) at a flow 
rate of 501.11/min. Eluting peptides were monitored in real-time by absorbance at 
215nm. Peptide fractions that appeared pure by chromatographical analysis were 
analyzed by automated Edman degradation using a Applied Biosystems 476A protein 
sequenator. 
5.3.6 PCR and cloning 
PCR primers were designed based both on peptide sequence information and 
conserved NAP-22 nucleotide sequence information from other species. Three primers 
were initially synthesized: NAP-22 forward primer (5'-AARCTGAGCAA GAAG 
AAGAAG-3') from  conserved  peptide  sequence  near NAP-22  n-terminus 
(KLSKKKK); NAP-22 reverse primer 1 (5'-YTCRTTNSWRCANGGYTT-3') from 
peptide  sequence information (KPCSNE); NAP-22 reverse primer 2  (5'­ 1 
YTGNACNG CNACNGTYTGRTC-3') from peptide  2  sequence  information 
(DQTVAVQ). Vector primers used were 5'- gill specific and 3'-gt11 specific vector 
primers from Stratagene (La Jolla, CA). 
NAP-22 forward primer was used in combination with 3' gill vector primer to span 
3' end of the coding region. NAP-22 reverse primers 1 and 2 were used individually in 
combination with 5' gtl 1 vector to span 5' end of the coding region. All reactions 
were set up in 20ial volumes as follows: lx PCR buffer (Promega), 1.25mM Mg2+, 
5% DMSO, 0.5mM dNTP's, 2units Taq polymerase, 0.51.IM each primer, 2111 cDNA 
library. PCR products were amplified using a MJ Research (Watertown, MA) 
thermocycler as follows: 20 cycles of 30 sec. at 94°C, 30 sec. at 65°C (minus 0.5°C per 92 
cycle), 1 min. at 72°C; followed by 20 cycles of 30 sec. at 94°C, 30 sec. at 55°C, 1 
min. at 72°C. The final cycle had an extended incubation of 5 min. at 72°C to ensure 
addition of A overhangs for TA cloning. 
PCR products were cloned using an Invitrogen (Carlsbad, CA) TA cloning kit as per 
manufacturer's instructions. Plasmid DNA was purified from transformed bacterial 
cells using a Qiagen Mini-Prep plasmid purification kit as per manufacturer's 
instructions. DNA sequencing was performed by the Center for Gene Research 
Laboratory at Oregon State University using an ABI 377 automated DNA sequencer. 
A second set of newt NAP-22 specific primers were synthesized based on the 
sequence information at the extreme 5' and 3' ends of the newt NAP-22 coding 
region. These primers were designed with a Ndel restriction site in the 5' primer and a 
BamH1 restriction site in the 3' primer for subcloning the PCR product into the pTM1 
mammalian expression  vector.  The newt  specific NAP-22  5'  primer  (5'­
GGAATTCCAT ATGGGAGGCAAGC TAAGCAAG-3') was used in combination 
with  the  newt  specific  NAP-22  3'  primer  (5'-CGCG 
GATCCCTCTTTGACGGCCACGCTTG-3') as above with the exception that Vent 
polymerase was used instead of Taq to minimize PCR introduced mutations. This 
clone, representing the entire coding sequence of newt NAP-22, was sequenced for 
verification and subcloned into pTM1 using the Ndel and BamHl restriction sites. 
5.3.7 Mammalian expression of NAP-22 and detection of full-length and myristylated 
proteins 
BSC40 cells were grown to confluency in 35 mm wells on 6-well plates (106 cells per 
well). The cells were cultured in Eagle's minimal essential medium (MEM) 
supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 10 µg /ml 
gentamycin-sulfate at 37°C in a 5% CO2 humidified atmosphere. Upon infection with 
vaccinia virus, the cells were then cultured in Eagle's MEM supplemented with 2 mM 93 
L-glutamine, 10 µg /ml gentamycin-sulfate at 37°C in a 5% CO2 humidified 
atmosphere. The cells were infected with vTF7-3, a T7 RNA polymerase-expressing 
recombinant vaccinia virus, at a multiplicity of infection of 10. Following a 1 hour 
virus adsorption period, the cells were transfected with 10 lig of pTM1:NAP22-6xHis. 
This plasmid contains the NAP22 cDNA behind a T7 promoter. The NAP22 sequence 
has been engineered so that its normal stop codon is absent and instead sequences 
which place a carboxy-terminal hexahistidine tag on the protein are present. The 
transfection was mediated by the transfection reagent DMRIE-C. At 4 hours post-
infection, the transfection reagents were removed from the cells and replaced with 
Eagle's MEM supplemented with 2 mM L-glutamine, 10 14/m1 gentamycin-sulfate 
containing 100 pCi/m1 [3H]- myristic acid. At 24 hours post-infection, the cells were 
harvested by washing them off the plate in the culture medium. The cells were pelleted 
from the medium by low-speed centrifugation. The cell pellet was resuspended in 100 
of phosphate-buffered  saline  (137 mM NaC1,  2.7 mM KC1,  4.3 mM 
Na2HPO4.7H20, 1.4 mM KH2PO4; PBS). 
A fraction of the cell extract was resolved by SDS-PAGE (21) on two identical gels. 
One gel was blotted to nitrocellulose and probed with Ni+-activated horse-radish 
peroxidase which binds histidine-tagged proteins. The blot was developed using 
chemiluminescent reagents and exposed to film. The other gel was fluorographed to 
detect tritium labeled proteins. The gel was dehydrated by immersion in dimethyl 
sulfoxide (DMSO) for 30 minutes. Then the gel was immersed in a 22.2% 
diphenyloxazole:DMSO solution for 1 hour. The diphenyloxazole was precipitated in 
the gel by immersion in water for 30 minutes. The gel was dried and exposed to film 
for detection of [3H]- myristic acid-label proteins. 
5.3.8 Ni-agarose pull-downs 
Transfected and mock-transfected BSC-40 cells were pelleted at low speed and 
homogenized with a teflon-on-glass tissue homogenizer in 25mM HEPES, pH 7.45). 94 
Total particulate lysate was pelleted at 20,000 x g and washed twice in 25mM HEPES, 
pH 7.45. Proteins were extracted from membranes as previously described ((19), 
Chapter 2, Chapter 3) for solubilization of newt P2 membrane pellets. Two 1 ml Ni­
agarose columns were prepared by pouring the Ni-agarose slurry into plastic 
chromatography columns and equilibrating with binding assay buffer (25mM HEPES, 
pH 7.45, 0.32% digitonin, 0.016% sodium cholate). Columns were loaded with 
detergent extract from either transfected or mock-transfected cells as 50% slurries, 
sealed, and incubated on a slow rocker at room temperature for 1 hour to produce the 
NAP-22 and control columns. Columns were drained, washed and loaded with newt 
neuronal membrane extract as 50% slurries, sealed, and incubated on a slow rocker at 
room temperature for  hour. Columns were drained and FT collected for 1 
[3H]corticosterone binding assays to evaluate any specific depletion of [3H]CORT 
binding activity by the NAP-22-Ni-agarose column relative to the control. 
5.4 Results 
5.4.1 Protein differential display 
A protein differential display scheme was developed (Fig. 5.1a) to identify mGR by 
2D SDS-PAGE following enrichment of the receptor from solubilized membrane 
extract by either corticosterone (CORT)-Sepharose or aldosterone (ALDO)- Sepharose 
affinity resins. This strategy was based on the observation that CORT-Sepharose will 
bind mGR whereas ALDO-Sepharose will not. Thus, eluents from CORT-Sepharose 
should contain mGR while eluents from ALDO-Sepharose should lack mGR. This 
strategy also relied on the premise that since ALDO is a corticosteroid and 
biochemically similar to CORT, the majority of non-specific interactions with other 
proteins would be similar for the two resins. Columns containing either of the two 
resins were loaded with membrane extract, washed, and eluted with a high salt, low 
pH shock to maximize efficient recovery of the receptor protein. [3H]CORT binding 
assays were performed on the flow-through (FT) and wash fractions from the two 95 
Figure 5.1. Affinity chromatography differential display. A) 1 ml of either CORT-
or ALDO-Sepharose was loaded with 1 ml membrane extract diluted to 2.5 ml 25mM 
HEPES, pH 7.45/0.5M NaCI and allowed to incubate as a slurry overnight at 4°C. 
Resins were then drained and washed with load buffer followed by elution with 1M 
NaCl, pH 4.0. Eluents were desalted with a centrifugal concentrator and proteins 
resolved by 2D gel electrophoresis followed by visualization of proteins using silver 
staining. Predominant differential spots are indicated by black arrows. B) FT and wash 
fractions were collected for [31-]CORT binding assays. A blank-Sepharose column 
was loaded as the others and used for a second control. 96 
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columns (Fig. 5.1b) These data showed that mGR was indeed captured by CORT-
Sepharose but not by ALDO-Sepharose. Eluents from both columns were visualized 
following resolution by 2D SDS-PAGE (Fig 5.1a). These gels show two protein spots 
as the predominant differences between the two gels. Both protein spots have apparent 
molecular weights of approximately 63kD, are running in the acidic region of the gel, 
and have a multi-spot pattern that is often representative of a glycosylated state. These 
observations are consistent with predictions from the preliminary biochemical 
characterization of mGR (chapter 2). 
The candidate spot closer to the extreme acidic end of the gel was chosen for further 
analysis because it was running in a well resolved region of the gel that would allow a 
single step purification by 2D gel electrophoresis. Preparative 2D gels were loaded 
directly with P2 membrane preparations from newt brains, stained with coomassie 
blue and the candidate spot excised for partial amino acid sequence analysis. After 
excision, the protein spot was digested with trypsin and the resultant peptides 
separated by HPLC. Peptide fractions were analyzed by automated Edman degradation 
to obtain peptide sequence information. Two peptides yielded n-terminal sequence 
(shown as underlined in Fig. 2a) and were used to search the Genbank protein 
database using BLAST (23). These peptides were positively identified as closely 
related neuronal axonal protein 22 (NAP-22) with 77% and 75% identity of peptide 1 
peptide 2, respectively, to bovine NAP-22 (BASP1). 
5.4.2 Cloning of NAP-22 
The peptide sequence information was used in combination with NAP-22 nucleotide 
sequence information from other species to design degenerate oligonucleotide PCR 
primers. These primers were used in combination with library vector primers to 
generate PCR products from a newt brain cDNA library which spanned either the 5' 
end or the 3' end of the coding region. PCR products were sequenced and confirmed 
to be the correct protein which was closely related to mammalian and avian NAP-22. 98 
The nucleotide sequence information from the extreme ends of the coding region was 
used to make newt NAP-22 specific primers to amplify a full-length cDNA product 
from the newt brain cDNA library. Three independent full-length clones were 
generated and sequenced to identify points of PCR introduced mutations. The 
nucleotide sequence for the open reading frame is given below (Fig. 5.2a) and the 
protein sequence is shown as an alignment with known NAP-22 sequences from other 
species (Fig. 5.2b). Calculations of percent identity between newt NAP-22 and that of 
other species revealed 37% identity to human, 36% identity to bovine, 28% identity to 
rat, and 28% identity to chicken homologs. 
5.4.3 Expression of NAP-22 
To evaluate the possibility that newt NAP-22 might be a membrane corticosterone 
receptor, the full length PCR product was subcloned into a mammalian expression 
vector and transfected into BSC-40 cells. Cells were allowed to grow for 24 hours 
post-transfection prior to harvesting for use in [3H]corticosterone binding assays. 
Since NAP-22 is known to be a myristyl-protein, myristylation was verified in the 
expression system with the use of [3H]myristic acid. A full length product was verified 
with the use of a c-terminal hexa-histidine tag (Fig 5.3). These data show that NAP-22 
was myristylated by the host cells and that full length protein product was obtained. 
Membranes were prepared from parallel transfected cells that received no [3H]myristic 
acid and used in [3H]CORT binding assays. These experiments showed no specific 
binding of [3H]CORT. As a control for influence of the hexahistidine tag, NAP-22 
clones lacking the tag were also expressed and used in radioligand binding assays, 
which yielded the same negative result. 99 
Figure 5.2. Newt NAP-22 sequence and alignment with known NAP-22 
sequences. Top, PCR amplified cDNA sequence from newt neuronal cDNA library 
with the deduced protein sequence superimposed. Original peptide sequences used for 
degenerate primer design are underlined. Bottom, newt NAP-22 sequence is aligned 
with that of human, cow, rat and chicken. Regions of 100% conservation are boxed. 
Multiple sequence alignments were generated with multalign software (53). 100 
ATGGGAGGCAAGCTAAGCAAGAAGAAGAAGGGGTACAATGTGAGTGATGACAAAGCAAAAGACAAGAAAGCTGATGGGGCAGCCCCT MGGK L SK K  K AK D  K ADGA AP K K G Y N V S  D D  K 
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Figure 5.3. Mammalian expression of newt NAP-22. NAP-22 in the pTM1 vector 
was transfected into BSC-40 cells and expression driven by infection with vaccinia 
virus. Myristylation of the transfected protein was verified by incubation of the 
transfected cells in media containing [3H]myristic acid. A full-length NAP-22 
transcript was verified by detection of a c-terminal hexa-histidine tag. The figure 
shows total particulate cell lysate from both mock transfected and NAP-22 transfected 
cells. The upper panel is taken from a western blot that was probed with India His-
Probe and visualized by ECL detection for detection of the hexahistidine tag. The 
lower panel is taken from a flourograph to detect [3H]myristyl-labeled proteins after 
incubation of the gel in PPO/DMSO. 102 
5.4.4 Protein-protein interaction studies with NAP-22 and mGR 
The non-denaturing conditions utilized in the differential display strategy, would have 
allowed for any receptor-associated proteins to maintain interaction with mGR and 
come through the differential display screen as candidate receptor proteins. The 
hypothesis that NAP-22 could be a mGR-associated protein was thus tested by 
protein-protein interaction 
studies. For these studies, mammalian expressed NAP-22 was produced with a c-
terminal hexa-histidine tag. Cell membranes were prepared and proteins extracted by 
non-denaturing detergents followed by capturing of NAP-22-His6 on Ni-Agarose. 
Newt neuronal membrane extract, containing the solubilized mGR, was then loaded 
onto the NAP-22-Ni-agarose. Flow-through fractions were assayed for depletion of 
[31-]CORT binding activity, which would indicate  an interaction of mGR and the 
NAP-22 column (Fig. 4). To control for non-specific binding to the column, a second 
Ni-agarose column was loaded with detergent extracted membranes from mock­
transfected cells prior to loading with solubilized receptor.  In two identical 
experiments a depletion of 36% and 15% of [3H]corticosterone binding activity was 
observed by the NAP-22 column, relative to the control. These data provide 
suggestive evidence  for an interaction between NAP-22 and the membrane 
corticosterone receptor and may explain the identification of NAP-22 by the 
differential display strategy. 
5.5 Discussion 
The current study identified newt NAP-22 by a protein differential display strategy 
designed to identify the newt neuronal mGR. Following its identification by partial 
amino acid sequencing, a full-length NAP-22 clone was obtained by PCR 
amplification from a newt brain cDNA library and successfully expressed in 
mammalian cells. The expressed protein was shown to be full-length using a c-
terminal hexahistidine tag and shown to be appropriately post-translationally modified 103 
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Figure 5.4. Ni-pull-down experiments with NAP-22. A) Hexa-histidine tagged 
NAP-22 was produced in mammalian cells and extracted from transfected membranes 
with detergent. Ni-agarose columns were then loaded with detergent extract from 
either NAP-22 transfected cell membranes or mock transfected cell membranes. 
Columns were then washed prior to loading with detergent extract from newt neuronal 
membranes and FT and wash fractions assayed for receptor binding activity using 
[3H]CORT binding assays (B). 104 
by myristylation. Membranes prepared from NAP-22 transfected cells lacked  any 
specific [3H]CORT binding activity. These data provided evidence against the 
hypothesis that NAP-22 is a functional CORT receptor. However, protein-protein 
interaction studies with the expressed NAP-22 and the native mGR in vitro, suggest a 
possible interaction between these two proteins and might explain the identification of 
NAP-22 by the differential display strategy. 
Comparison of the deduced amino acid sequence with that of NAP-22 (CAP-23, 
BASP1) from human, bovine, rat, and chicken provided strong evidence that the newt 
clone is indeed a NAP-22 homolog. The highest degree of conservation across all five 
species was seen in the n-terminus, which is also the site of myristylation, suggesting 
an important role for this region of the molecule. It is interesting that the c-terminus of 
newt NAP-22 shares much more homology with the mammalian clones than with the 
avian clone, which is highly divergent in this region. This suggests that the divergence 
of chicken NAP-22 in the c-terminal region occurred after the divergence of birds and 
amphibians. 
The migration of newt NAP-22 on 2D SDS-PAGE is consistent with it's known 
properties. NAP-22 is an unusually acidic protein with a calculated pI of 4.69 and a 
calculated mass of 22 kDa, however, it is reported to run anomalously on SDS-PAGE 
with an observed migration between 45-65 kDa (24). These are consistent with our 
observations, locating NAP-22 in the highly acidic region of the 2D gel with an 
apparent molecular weight of approximately 63 kDa. Interestingly, this migration was 
also consistent with the expectations of mGR based on a preliminary biochemical 
characterization, which suggests mGR to be an acidic protein with an apparent 
molecular weight of 63 kDa (Chapter 3). However, more recent studies with mGR, 
using an azido-CORT ligand to photolabel the receptor, identified a candidate receptor 
protein running at a more basic position with a pI of approximately 5.0 (Chapter 3). 
Also, the newt neuronal mGR is believed to be a glycoprotein (Chapter 3), which 
NAP-22 is unlikely to be since it is an intracellular peripheral membrane protein. The 
multi-spot pattern of NAP-22, consistent with a glycosylated state, may instead be due 105 
to different phosphorylation states because NAP-22 is known to be a phosphoprotein 
(25). The lack of [3H]CORT binding activity, the probable lack of glycosylation, and 
the identification of a spot different from NAP-22 with the azido-CORT photolabel 
(Chapter 3) make it unlikely that NAP-22 is mGR. 
The observation that NAP-22 might interact with mGR in vitro may provide some 
explanation as to why the migration of NAP-22 on the 2D gel was consistent with that 
expected for mGR. If NAP-22 and mGR do indeed form a complex, then the extreme 
acidity of NAP-22 could influence the behavior of the receptor complex on 
chromatographic resins, which were used, in part, to biochemically characterize mGR 
(Chapter 3). The fact that ion exchange and hydroxylapatite chromatographies suggest 
mGR to be a highly charged, acidic protein might be due to an interaction with NAP­
22 (Chapter 3). 
NAP-22 has previously been shown to be a peripheral membrane protein that is 
associated with the  cytosolic face of plasma or vesicular membranes by a 
myristylation anchor (26-28). It is structurally related to two other known proteins, 
GAP-43 and MARCKS. These proteins share physiochemical properties and sub-
cellular localization (25) even though they are not highly related by amino acid 
sequence. Also, all have been shown to be substrates for phosphorylation by protein 
kinase C (PKC) (29-32) and all are calmodulin binding proteins (33-36). This small 
family of proteins has been implicated in the control of membrane dynamics and 
control of neurotransmitter release (37-43). In addition to these roles, GAP-43 has 
been shown to directly activate a subset of G-proteins as well as potentiate signals 
through some known G-protein coupled receptors (44-49). These observations are 
interesting because they provide support for a relationship between this family of 
proteins and the signal transduction machinery of G-protein coupled receptors, which 
mGR is suspected to be. 
The current observations, relating NAP-22 to mGR, are consistent with previous 
studies of membrane effects of glucocorticoids. CORT has been shown to rapidly 106 
increase binding of [125I]calmodulin in highly purified synaptic vesicles (50,51). Since 
NAP-22 is a calmodulin binding protein, perhaps these data can be explained by the 
induction of calmodulin binding by NAP-22 following activation of mGR by CORT. 
A rapid effect of CORT on the release of corticotropin-releasing factor (CRF) from 
hypothalamic synaptosomes has also been shown (52). Since NAP-22 has been 
implicated in the control of neurotransmitter release, perhaps NAP-22 is involved in 
this action of CORT as well. 
The current report provides the first example of the identification and cloning of NAP­
22 from and amphibian source. The context in which this protein was identified in 
combination with protein-protein interaction studies suggests a possible role for NAP­
22 as a membrane glucocorticoid receptor-associated protein.  Future  studies 
addressing this hypothesis would be facilitated by the molecular cloning of the newt 
neuronal mGR, which is an ongoing effort in our laboratory. 
It is interesting that the only other spot that appeared positive in the differential 
display screen of the current study, is also an acidic protein with an apparent 
molecular weight of approximately 63 kDa, and has a multi-spot pattern consistent 
with a glycosylated state. This protein is yet unidentified but is running very close to, 
if not identical to, the spot identified with the azido-CORT photolabel (Chapter 3). It 
is difficult to determine from the current data if the proteins identified by these two 
techniques are identical because of the slight variances in 2D gels and the complexity 
of the protein mixture. This second protein identified in the current study, however, 
may actually be the CORT binding site. 
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Chapter 6 
Summary and Future Directions 
6.1 Results and Conclusions 
The work described in this thesis was aimed at discovering the molecular identity of a 
membrane glucocorticoid receptor (mGR) in the brain of an amphibian, the roughskin 
newt (Taricha granulosa). Although sequencing and cloning of this receptor was not 
achieved, new information about pharmacological and biochemical characteristics of 
mGR were elucidated. Chapter 2 described the solubilization of active mGR from 
newt neuronal membranes. This work provided the basis for further biochemical 
characterization, which is the subject of the Chapter 3. This Chapter described the use 
of classic chromatographic techniques in combination with an immobilized ligand 
affinity resin to enrich the mGR protein and elucidate some of its biochemical 
properties. Chapter 3 also described the production and use of a photoaffinity ligand 
that identified the mGR protein on a 2D gel. These studies suggest that mGR is a 
glycoprotein with an apparent molecular weight of 63 kDa and an isoelectic point of 
approximately 5.0. These data provided further evidence that mGR is distinct from the 
intracellular glucocorticoid receptor (GR). Chapter 4 discussed experiments that 
showed mGR to specifically interact with a subset of kappa opioid ligands. These data 
suggest that mGR may be related to the kappa opioid receptor. Finally, Chapter 5 
described the identification and cloning of a protein, NAP-22, from newt brain. This 
was the first report identifying NAP-22 from an amphibian source. Data suggest that 
this protein may be a mGR-associated protein, possibly a member of the receptor's 
signal transduction machinery. 111 
6.2 Future directions 
In addition to the contributions made by this thesis to our understanding of the newt 
neuronal mGR, several questions were raised that can be addressed with future 
studies. First, the identification of a putative mGR protein on a 2D gel with the 
photoaffinity label raises the following technical question: "Can the newt neuronal 
mGR be purified and identified by this methodology?" This question is important 
because the limited tissue obtained from newt brain imposed difficult technical 
problems for a protein purification project, which usually require large amounts of 
starting material. Thus identification of mGR on a 2D gel may circumvent this 
problem by allowing a single step purification to maximize receptor yield. Second, the 
identification of NAP-22 as a possible mGR-associated protein raises two questions. 
"Is NAP-22 involved in the signal transduction machinery of mGR or any other 
receptor? Can NAP-22 affect neurotransmitter release in response to a specific 
hormonal stimulus, like corticosterone?" These questions might lead to a better 
mechanistic understanding of how corticosterone can rapidly effect behavior. Third, 
the evidence that mGR may be a kappa-opioid-like receptor leads to two other 
questions. "Do glucocorticoids affect signaling in the opioid system? Does activation 
of the opioid system affect signaling through mGR?" Future studies aimed at 
answering these questions could lead to the molecular identification and cloning of 
mGR, as well as an understanding of its function in a broader endocrine context. 
The hypothesis that mGR is a kappa opioid-like receptor is consistent with the results 
of previous studies as well as the findings of this thesis. In newts, AVT stimulates sex 
behavior (1) and CRH stimulates locomotor behavior (2). Both of these neuropeptides 
induce the release of ACTH from the pituitary (3), which leads to the release of 
glucocorticoids from the adrenal glands (4). Glucocorticoids inhibit sex behavior (5) 
and locomotor behavior (6) in newts, providing a possible feedback loop for the 
control of these behaviors. Furthermore, glucocorticoids have been reported to inhibit 112 
both CRH (7) and AVT release (8), providing a possible mechanism for this feedback 
control. Kappa agonists have also been shown to inhibit both sex behavior (9) and 
locomotor behavior (10) in newts, and have been shown to inhibit CRH (11) and AVT 
(12) release from pre-synaptic membranes. The findings of this thesis that mGR may 
be a kappa-opioid like receptor is thus, intriguing, given the similar involvement of 
glucocorticoids and kappa opioid receptors in the control of AVT and CRH release, 
and the control of reproductive and locomotor behaviors in newts. Figure 6.1 
summarizes these data with a model that may explain some nongenomic effects of 
glucocorticoids through a kappa-opioid like receptor. 
The progress made by the work described in this thesis towards the molecular 
identification of mGR and its physiological roles, contribute a small piece to the larger 
puzzle of understanding nongenomic steroid hormone actions. It is unlikely that 
genomic and nongenomic effects of steroids are independent of each other and a 
complete understanding of steroid hormone action will not be realized until both 
mechanisms are integrated. A hypothetical example can be envisioned in which 
nongenomic and genomic actions of a steroid are coordinated to affect specific 
physiological responses. A steroid could induce rapid effects through a nongenomic 
process that could then be modulated by the slower genomic mode of action, 
providing a feedback response from a single signal. This could occur at the cellular 
level with the co-localization of intracellular and membrane receptors in the same cell; 
or on a broader scale with the rapid activation of an endocrine system by nongenomic 
effects that could be modulated by slower genomic actions. Such an example could 
apply to the physiological actions of glucocorticoids, which have acute effects that are 
often opposed to the chronic effects of prolonged glucocorticoid exposure. 
Future studies with the newt neuronal mGR as well as other membrane steroid 
receptors will provide a greater understanding of the roles these proteins have in 
mediating and integrating the effects of steroid hormones. This basic research will lead 
to a greater appreciation for the functions of steroids in physiology and behavior as 113 
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Figure 6.1 Model for nongenomic actions of glucocorticoids through a kappa 
opioid-like receptor. Glucocorticoids are shown to signal through a kappa-opioid like 
receptor to inhibit the release of CRH and AVT to effectively inhibit sex behavior and 
locomotor behavior, which are known activities of the kappa opioid receptor. 114 
well as improve our current therapeutic uses of this clinically important class of 
hormones. 
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Appendix 1 
Observations about the Relationship Between
 
Structural Components of Steroids and Functional Activity at mGR
 
Many different steroids have been tested for activity in [311]CORT competition assays 
for binding activity at mGR. This has allowed an observational evaluation of 
important structural components within the steroid molecule for interactions with the 
mGR binding site (Fig. A.1). A comparison of corticosterone to cortisol, which varies 
only by the addition of a hydroxyl group at position 17 of the cortisol molecule, 
suggests the importance of this region of the steroid for binding activity. The 17­
hydroxy addition decreases affinity for mGR by approximately 8-fold. This might be 
due to compromising the ability of the carbonyl group at position 20 to act as a 
hydrogen acceptor. Comparing corticosterone to either aldosterone or progesterone 
suggests a role for the hydroxyl group at position 11. The 11-hydroxy group of 
corticosterone is moved in aldosterone to position 18 and absent in progesterone. This 
change causes a loss of affinity of several hundred fold. Perhaps the 11-hydroxy group 
acts as a hydrogen donor, an ability that has been compromised in the aldosterone 
molecule and lost in the progesterone molecule. Dexamethasone, which lacks affinity 
at mGR has compromised both the hydrogen acceptor capabilities of the 20-carbonyl 
group and the hydrogen donor capabilities of the 11-hydroxy group, providing support 
for the importance of these structural components. Azido-CORT maintains the 
integrity of both the 20-carbonyl and 11-hydroxy groups, yet shows a loss of affinity 
of approximately 400-fold. This might be explained by the flexibility of the 
carboxymethyloxime linker arm that would allow interaction between the 11-hydroxy 
group and the nitrosyl group of the aryl ring. These observations suggest that a 
hydrogen donor at position 11 and a hydrogen acceptor at position 20 may be 
important structural components of steroidal ligands for activity at mGR. Testosterone 
is an interesting case because it lacks both of these components yet has low affinity for 
mGR, suggesting that some other structural component is involved in the interaction 
between steroids and mGR. 137 
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Figure A.1. Structures of steroidal ligands and affinities for mGR. Steroids are 
arranged in order of affinity from top to bottom. K1 values are relative to competition 
with [3H]CORT for the mGR binding site. 